Electromagnetic sensing devices and methods for lateral flow assays

Electronic sensors integrated with adhesive substrates in LFAs address the limitations of visual interpretation by enhancing sensitivity and accuracy, enabling rapid, quantitative analysis of infectious diseases and biomarkers.

JP2024542230APending Publication Date: 2024-11-1311281232 CANADA INC
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024529812
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-17
Filing Date
2022-11-17
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Lateral flow assays (LFAs) face challenges in providing accurate, quantitative results due to reliance on visual interpretation, which can lead to false negatives and positives, and are limited in detecting low analyte concentrations, especially for infectious diseases like COVID-19 and biomarkers such as prostate-specific antigen.

Method used

Integration of electronic sensors, such as capacitive and inductive sensors, onto a planar element with an adhesive substrate to ensure precise alignment and minimize air gaps, allowing for continuous electromagnetic sensing and accurate detection of analytes, including infectious disease biomarkers, by measuring changes in resonant frequency.

Benefits of technology

Enhances the accuracy and sensitivity of LFA results, enabling rapid, quantitative analysis of analytes with improved signal-to-noise ratio, reducing false positives and negatives, and allowing for at-home testing of infectious diseases and biomarkers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542230000001_ABST
    Figure 2024542230000001_ABST
Patent Text Reader

Abstract

There is provided a test device for assessing at least one test substance comprising a planar element, at least one electronic sensor arranged on the planar element for sensing at least one sensing area of ​​the lateral flow test element for assessing the at least one test substance, and an adhesive substrate connected to a surface of the planar element and configured to connect to a surface of the lateral flow test element.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention in some embodiments thereof relates to medical diagnostic devices, and more particularly, but not exclusively, to lateral flow based medical devices. [Background technology]

[0002] Lateral flow assays (LFAs) are ubiquitous in the field of rapid diagnostics, with the most common application of this technology being pregnancy testing. Today, LFAs can also detect infectious diseases such as COVID-19 and biomarkers such as prostate-specific antigen. Summary of the Invention [Means for solving the problem]

[0003] A first aspect is a test device for assessing at least one test substance, comprising a planar element, at least one electronic sensor arranged on said planar element for sensing at least one sensing area of ​​a lateral flow test element for assessing at least one said test substance, and an adhesive substrate connected to a surface of said planar element and configured to connect to a surface of said lateral flow test element.

[0004] In another implementation of the first aspect, the adhesive substrate is spread over the surface of the planar element and configured to spread over the surface of the lateral flow test element.

[0005] In another implementation of the first aspect, the adhesive substrate comprises a first adhesive counter surface and a second adhesive counter surface, the first adhesive counter surface configured to connect to the surface of the planar element and the second adhesive counter surface configured to connect to the surface of the lateral flow test element.

[0006] In another implementation of the first aspect, the adhesive substrate is selected from the group consisting of an adhesive, a tape, a self-adhesive, and a spray-on adhesive.

[0007] In another implementation of the first aspect, the device further comprises the lateral flow test element.

[0008] In another implementation of the first aspect, the adhesive substrate positions at least one of the sensing areas in proximity to at least one of the electronic sensors.

[0009] In another implementation of the first aspect, the distribution of the adhesive substrate is selected to exclude a large amount of air from being present between at least one of the sensing areas and at least one of the electronic sensors.

[0010] In another implementation of the first aspect, the adhesive substrate is sandwiched between the surface of the planar element and the surface of the lateral flow test element.

[0011] In another implementation of the first aspect, the adhesive substrate is sandwiched between at least one of the electronic sensors and an area of ​​the lateral flow test element that includes at least one of the sensing regions.

[0012] In another implementation of the first aspect, the adhesive substrate is at least positioned over at least one of the electronic sensors and at least one of the sensing areas, and an area of ​​the lateral flow test element including at least one of the sensing areas is aligned with and faces the at least one of the electronic sensors.

[0013] In another implementation of the first aspect, at least one of the sensing regions of the lateral flow test element comprises an analyte binding element designed to bind to at least one of the analytes administered to the lateral flow test element.

[0014] In another implementation of the first aspect, the planar element replaces the backing card of the lateral flow test element, acting as a physical support component for the lateral flow test element.

[0015] In another implementation of the first aspect, the thickness of the adhesive substrate is selected to be thin to obtain a sufficiently strong signal above a threshold from the at least one electronic sensor sensing at least one of the sensing areas for evaluation of at least one of the test substances.

[0016] In another implementation of the first aspect, the surface of the planar element has a size that is at least the size of the surface of the lateral flow test element.

[0017] In another implementation of the first aspect, the planar element includes a printed circuit board (PCB), and the at least one electronic sensor is at least one of connected to the PCB and integrated with the PCB.

[0018] In another implementation of the first aspect, the lateral flow test element further comprises at least one second electronic sensor disposed on the planar element for sensing at least one reference region of the lateral flow test element that is substantially free of analyte binding elements, and at least one of the analytes administered to the lateral flow test element flows across at least one of the reference regions without substantially selectively binding to the reference region.

[0019] In another implementation of the first aspect, a signal output by at least one second electronic sensor sensing at least one second region is analyzed to assist in measuring at least one of the test substances.

[0020] In another implementation form of the first aspect, at least one of the sensing areas includes an inspection area and a reference area different from the inspection area, and at least one of the electronic sensors includes an inspection electronic sensor arranged on the planar element for sensing the inspection area and a reference electronic sensor arranged on the planar element for sensing the reference area.

[0021] In another implementation of the first aspect, at least one of the sensing areas includes a test substance binding element designed to bind to at least one of the test substances corresponding to a biomarker of an infectious disease to assess the presence of an infectious disease in a user.

[0022] In other implementations of the first aspect, the infectious disease biomarkers include markers for at least one of a sexually transmitted disease and COVID-19.

[0023] In another implementation of the first aspect, at least one of the sensing regions includes a test substance binding element designed to bind to at least one of the test substances corresponding to a health-related biomarker for assessing a relevant health condition in a user.

[0024] In another implementation of the first aspect, the health-related biomarker is selected from the group consisting of cortisol, melatonin, testosterone, and progesterone.

[0025] In another implementation of the first aspect, at least one of the electronic sensors is designed to generate an electromagnetic field that follows electric field lines originating from the at least one of the electronic sensors, passing through the adhesive substrate, passing through at least one of the sensing areas, passing back through the at least one of the adhesive substrates, and returning to the at least one of the electronic sensors.

[0026] In another implementation of the first aspect, the at least one electronic sensor includes at least one capacitive sensor for capacitive sensing.

[0027] In another implementation of the first aspect, each capacitive sensor includes an interdigitated arrangement of a pair of electrodes.

[0028] In another implementation of the first aspect, the at least one electronic sensor includes at least one inductive sensor for inductive sensing.

[0029] In another implementation of the first aspect, each inductive sensor includes at least one planar coil having at least one layer.

[0030] In another implementation of the first aspect, the device further includes a circuit configured to operate the at least one inductive sensor at a resonant frequency.

[0031] In another implementation of the first aspect, the device further includes a controller configured to operate at a sampling frequency and measure a change in the resonant frequency of at least one of the electronic sensors indicative of binding of at least one of the test substances to at least one of the sensing areas.

[0032] In another implementation of the first aspect, the resonant frequency of the at least one electronic sensor is in a range of 0.001 to 40 megahertz (MHz).

[0033] In another implementation of the first aspect, a label selected to exhibit superparamagnetic properties is used to identify the presence of at least one of the analytes.

[0034] In another implementation of the first aspect, the device further includes a transmitter configured to transmit a signal sensed by at least one of the electronic sensors to an external computing device for analysis of the signal to determine the presence of at least one of the test substances.

[0035] In another implementation of the first aspect, the test device is implemented as a disposable device designed to be discarded after a liquid sample has been applied to the lateral flow test element, the liquid sample flows by capillary action through the lateral flow test element and reaches a wick, and at least one of the analytes, when present in solution, binds to an analyte binding element in at least one of the sensing regions.

[0036] A second aspect is a computer-implemented method for evaluating at least one analyte, comprising receiving a signal obtained from at least one electronic sensor of a test device, the at least one electronic sensor being disposed on a planar element of the test device for sensing at least one sensing area of ​​a lateral flow test element, the at least one sensing area comprising an analyte binding element designed to bind to at least one of the analytes administered to the lateral flow test element, an adhesive substrate being connected to a surface of the planar element and to a surface of the lateral flow test element for fixing the at least one electronic sensor in a position facing an area of ​​the lateral flow test element comprising at least one of the sensing areas, analysing the signal to measure accumulation of the at least one analyte in at least one sensing area of ​​the lateral flow test element, and determining at least one of evidence indicative of the presence of the at least one analyte, a concentration of the at least one analyte, and evidence indicative of the absence of the presence of the at least one analyte.

[0037] In another implementation of the second aspect, the at least one electronic sensor is selected from the group consisting of at least one capacitive sensor for capacitive sensing and at least one inductive sensor for inductive sensing.

[0038] In another implementation of the second aspect, the method further includes determining at least one of a diagnosis, prognosis, or trend of a medical condition, or an analysis of a health condition, if at least one of the following is met: at least one of the test substances is detected, at least one of the test substances is not detected, a concentration of at least one of the test substances is above a threshold, and a concentration of at least one of the test substances is below the threshold.

[0039] In another implementation of the second aspect, the method further includes establishing a communications session with a remote client terminal of a healthcare provider and / or a public health entity in response to the diagnosis, prognosis, or trend.

[0040] In another implementation of the second aspect, the method further includes administering to the user a therapy effective to treat the medical condition.

[0041] In another implementation of the second aspect, the method further includes determining concentrations of wellness biomarkers that include non-diagnostic information and automatically communicating the non-diagnostic information to a client terminal via a connected smart device.

[0042] In another implementation of the second aspect, the health condition is a non-reportable, non-life threatening health condition that does not require diagnosis by a medical professional and is classified by various biomarker levels.

[0043] In other implementations of the second aspect, the biomarker is selected from the group consisting of salivary cortisol, blood-based cortisol, testosterone, interleukin-6 (IL-6), tetrahydrocannabinol (THC) influenza A, influenza B, group A streptococcus, procalcitonin, C-reactive protein, and Escherichia coli.

[0044] In another implementation of the second aspect, the medical condition is an infection with an infectious agent.

[0045] In other implementations of the second aspect, the infectious disease pathogen is selected from the group consisting of a sexually transmitted disease and COVID-19.

[0046] In another implementation of the second aspect, analyzing includes providing the signal to a machine learning model trained on a training dataset including a plurality of records, each record including a sample signal labeled with at least one ground truth indicator of evidence of the presence of at least one of the analytes, evidence of the absence of the presence of at least one of the analytes, and a concentration of at least one of the analytes.

[0047] In another implementation of the second aspect, the received signal is calculated from signals output by a test electronic sensor sensing at least one of the sensing areas and a reference electronic sensor sensing a reference area different from at least one of the sensing areas, and at least one of the test substances that bind to the test substance binding element in at least one of the sensing areas does not selectively bind to the reference area.

[0048] A third aspect is a method of manufacturing a test device comprising: rolling out a plurality of rolls comprising components for creating a plurality of test devices; rolling out a roll of a flexible planar element having a plurality of spaced apart electronic sensors arranged thereon; laminating an adhesive substrate onto a surface of the flexible planar element; laminating components for creating a plurality of the test devices onto the adhesive substrate to create a master assembly; and slicing the master assembly into a plurality of slices, each slice representing a respective test device of the plurality of the test devices for evaluating the presence, absence, and / or concentration of at least one analyte in an applied sample.

[0049] In another implementation of the third aspect, the flexible planar element includes a flexible printed circuit board (PCB).

[0050] In another implementation of the third aspect, the method further includes unrolling a roll of self-adhesive tape and laminating the unrolled self-adhesive tape onto the surface of the flexible planar element, the laminating including sandwiching the self-adhesive tape between the planar element and the components of the plurality of inspection devices.

[0051] In another implementation of the third aspect, the slicing includes slicing along a width of the master assembly between adjacent electronic sensors.

[0052] In another implementation of the third aspect, each respective test device comprises a planar element of the roll of flexible planar elements, at least one electronic sensor of the plurality of electronic sensors of the roll of flexible planar elements, and an adhesive substrate connected to a surface of the planar element and to a surface of the lateral flow test element for fixing at least one of the electronic sensors in a position facing at least one of the sensing areas comprising a test substance binding element designed to bind to at least one of the test substances administered to the lateral flow test element.

[0053] A fourth aspect is a test device for evaluating a test substance comprising a planar element, at least one electronic sensor arranged on the planar element for sensing at least one sensing area of ​​a lateral flow test element for evaluating the test substance, and an adhesive substrate connected to a surface of the planar element and configured to connect to a surface of the lateral flow test element.

[0054] In another implementation of the first or fourth aspect, the adhesive substrate is spread over the surface of the planar element and over the surface of the lateral flow test element.

[0055] In other implementations of the first or fourth aspects, the adhesive substrate includes an insignificant amount of air that does not significantly affect signal transmission, and the insignificant amount of air is present in the adhesive substrate in continuous contact between the at least one electronic sensor and the at least one sensing area.

[0056] In another implementation of the first or fourth aspect, the adhesive substrate comprises an adhesive substrate having a first adhesive counter surface and a second adhesive counter surface, the first adhesive counter surface being configured to connect to the surface of the planar element and the second adhesive counter surface being configured to connect to the surface of the lateral flow test element.

[0057] In another implementation of the first or fourth aspect, the adhesive substrate comprises an adhesive.

[0058] In another implementation of the first or fourth aspect, the adhesive substrate is sandwiched between the surface of the planar element and the surface of the lateral flow test element.

[0059] In another implementation of the first or fourth aspect, the adhesive substrate is sandwiched between at least one of the electronic sensors and an area of ​​the lateral flow test element that includes at least one of the sensing regions.

[0060] In other implementations of the first or fourth aspect, the adhesive substrate is at least positioned over at least one of the electronic sensors and at least one of the sensing areas, such that an area of ​​the lateral flow test element including at least one of the sensing areas is aligned with and faces the at least one of the electronic sensors.

[0061] In other implementations of the first or fourth aspect, the thickness of the adhesive substrate is selected to be thin in order to obtain a sufficiently strong signal above a threshold from at least one electronic sensor sensing at least one sensing area for evaluation of the test substance.

[0062] In other implementations of the first or fourth aspect, the surface of the planar element has a size at least as large as the surface of a lateral flow test element.

[0063] In other implementations of the first or fourth aspect, the test device further comprises a lateral flow test element.

[0064] In another implementation of the first or fourth aspect, at least one of the sensing regions of the lateral flow test element comprises an analyte binding element designed to bind to the analyte administered to the lateral flow test element.

[0065] In another implementation of the first or fourth aspect, the planar element includes a printed circuit board (PCB), the PCB replaces the backing card of the lateral flow test element, and the at least one electronic sensor is at least one of connected to the PCB and integrated with the PCB.

[0066] In other implementations of the first or fourth aspect, the backing card of the lateral flow test element is affixed to the planar element, the backing card acting as a physical support component for the lateral flow test element.

[0067] In another implementation of the first or fourth aspect, the test device further comprises at least one second electronic sensor disposed within the planar element for sensing at least one reference region of the lateral flow test element that excludes analyte binding elements, and the analyte administered to the lateral flow test element flows across at least one of the reference regions without selectively binding to the reference region.

[0068] In other implementations of the first or fourth aspect, a signal output by at least one second electronic sensor sensing at least one second region is analyzed to assist in detecting the presence of the test substance.

[0069] In another implementation form of the first or fourth aspect, at least one of the sensing areas includes an inspection area and a reference area different from the inspection area, and at least one of the electronic sensors includes an inspection electronic sensor arranged on the planar element for sensing the inspection area and a reference electronic sensor arranged on the planar element for sensing the reference area.

[0070] In other implementations of the first or fourth aspect, at least one of the sensing areas includes a test substance binding element designed to bind to the test substance including a biomarker for an infectious disease to assess the presence of the infectious disease in a user.

[0071] In other implementations of the first or fourth aspect, the infectious disease biomarkers include markers for at least one of a sexually transmitted disease and COVID-19.

[0072] In other implementations of the first or fourth aspects, at least one of the electronic sensors is designed to generate an electromagnetic field that follows electric field lines originating from the at least one of the electronic sensors, passing through the adhesive substrate, passing through at least one of the sensing areas, passing back through the at least one of the adhesive substrates, and returning to the at least one of the electronic sensors.

[0073] In another implementation of the first or fourth aspect, the at least one electronic sensor includes at least one capacitive sensor for capacitive sensing.

[0074] In other implementations of the first or fourth aspects, each capacitive sensor includes an interdigitated arrangement of a pair of electrodes.

[0075] In another implementation of the first or fourth aspect, the at least one electronic sensor includes at least one inductive sensor for inductive sensing.

[0076] In another implementation of the first or fourth aspect, each inductive sensor includes at least one planar coil having at least one layer.

[0077] In another implementation of the first or fourth aspect, the sensing device further includes a circuit configured to operate the at least one inductive sensor at a resonant frequency.

[0078] In another implementation of the first or fourth aspect, the testing device further includes a controller configured to operate at a sampling frequency and measure a change in the resonant frequency of at least one of the electronic sensors, which is indicative of binding of the test substance to at least one of the sensing areas.

[0079] In another implementation of the first or fourth aspect, the resonant frequency of at least one of the electronic sensors is in the range of 1 to 10 megahertz (MHz).

[0080] In other implementations of the first or fourth aspect, a label selected to exhibit superparamagnetic properties is used to identify the presence of the analyte.

[0081] In other implementations of the first or fourth aspects, the testing device further includes a transmitter configured to transmit a signal sensed by at least one of the electronic sensors to an external computing device for analysis of the signal to detect the presence of the test substance.

[0082] In another implementation of the first or fourth aspect, the test device is a disposable device designed to be discarded after a liquid sample is applied to the lateral flow test element, the liquid sample flows through the lateral flow test element by capillary action and reaches a wick, and the analyte, when present in solution, binds to the analyte binding element in at least one of the sensing regions.

[0083] A fifth aspect is a computer-implemented method for evaluating a test substance, comprising receiving a signal obtained from at least one electronic sensor of a test device, the at least one electronic sensor being selected from the group including at least one capacitive sensor for capacitive sensing and at least one inductive sensor for inductive sensing, the at least one electronic sensor being disposed on a planar element of the test device for sensing at least one sensing area of ​​a lateral flow test element, the at least one test area comprising an analyte binding element designed to bind to the test substance administered to the lateral flow test element, an adhesive substrate being connected to a surface of the planar element and to a surface of the lateral flow test element for fixing the at least one electronic sensor in a position facing an area of ​​the lateral flow test element comprising at least one sensing area, analysing the signal to measure accumulation of the test substance in at least one sensing area of ​​the lateral flow test element and determining at least one of the following: the presence of the test substance, the concentration of the test substance, and absence of evidence of the presence of the test substance.

[0084] In other implementations of the second or fifth aspect, the method further includes determining a diagnosis, prognosis, or trend of a medical condition, or health status if at least one of the following is met: the test substance is present, the test substance is absent, the concentration of the test substance is above a threshold, and the concentration of the test substance is below the threshold.

[0085] In other implementations of the second or fifth aspect, the medical condition is an infection by an infectious disease agent.

[0086] In other implementations of the second or fifth aspect, the infectious disease pathogen is selected from the group consisting of COVID-19, and a sexually transmitted disease, a respiratory infection, a hormonal marker indicative of a health condition, a protein marker indicative of an infectious disease or health condition, a nucleic acid-based marker indicative of an infectious disease or health condition, and a marker indicative of drug use.

[0087] In other implementations of the second or fifth aspect, the liquid sample is selected from the group consisting of blood, saliva, urine, and sweat.

[0088] In other implementations of the second or fifth aspect, the method further includes establishing a communication session with a remote client terminal of a healthcare provider and / or a public health entity in response to the diagnosis.

[0089] In other implementations of the second or fifth aspect, the method further comprises administering to the user a therapy effective to treat said medical condition.

[0090] In other implementations of the second or fifth aspect, treatment can be understood to refer to both medical (drugs, treatments, etc.) and non-medical (diet, exercise, supplements, habits, etc.) types of treatment.

[0091] In other implementations of the second or fifth aspect, analyzing includes providing the signal to a machine learning model trained on a training dataset including a plurality of records, each record including a sample signal labeled with at least one ground truth indicator of evidence of the presence of the analyte, absence of evidence of the presence of the analyte, and a concentration of the analyte.

[0092] In another implementation form of the second or fifth aspect, the received signal is calculated from signals output by a test electronic sensor sensing at least one of the test areas and a reference electronic sensor sensing a reference area different from the at least one of the test areas, and the test substance that binds to the test substance binding element in at least one of the sensing areas does not selectively bind to the reference area.

[0093] A sixth aspect is a method of manufacturing a lateral flow test device comprising: rolling out a plurality of rolls comprising components for creating a plurality of lateral flow test elements; rolling out a roll of a flexible planar element having a plurality of spaced apart electronic sensors arranged thereon; laminating an adhesive substrate onto a surface of the flexible planar element; laminating components for creating a plurality of the lateral flow test elements onto the adhesive substrate to create a master assembly; and slicing the master assembly into a plurality of slices, each slice representing a respective test device for assessing the presence, absence of evidence of the presence, and / or concentration of an analyte in an applied sample.

[0094] In another implementation of the third or sixth aspect, the flexible planar element includes a flexible printed circuit board (PCB).

[0095] In another implementation of the third or sixth aspect, the method further includes unrolling a roll of self-adhesive tape and laminating the unrolled self-adhesive tape onto the surface of the flexible planar element.

[0096] In another implementation of the third or sixth aspect, the slicing includes slicing along a width of the master assembly between adjacent electronic sensors.

[0097] In another implementation of the third or sixth aspect, each respective test device comprises a lateral flow test element of a plurality of lateral flow test elements, a planar element of the roll of flexible planar elements, at least one electronic sensor of the plurality of electronic sensors of the roll of flexible planar elements, and an adhesive substrate connected to a surface of the planar element and to a surface of the lateral flow test element for fixing at least one of the electronic sensors in a position facing at least one of the sensing areas comprising a test substance binding element designed to bind to the test substance administered to the lateral flow test element. [Brief description of the drawings]

[0098] [Figure 1] FIG. 1 is a block diagram of components of a system for evaluating a test substance according to some embodiments of the present invention. [Diagram 2] FIG. 2 is a schematic diagram of components for assembling an exemplary test device for evaluation of an analyte, according to some embodiments of the present invention. [Diagram 3] FIG. 3 is a schematic diagram illustrating a process of assembling a testing device from components such as those described with reference to FIG. 2, according to some embodiments of the present invention. [Figure 4A] FIG. 4A is a schematic diagram of electric field lines passing between sensors of a planar element of a sensing device according to some embodiments of the present invention. [Figure 4B] FIG. 4B is a schematic diagram of magnetic field lines passing through a sensor of a planar element of a sensing device according to some embodiments of the present invention. [Diagram 5] FIG. 5 is a schematic diagram of an assembled testing device shown in perspective and cross-sectional views according to some embodiments of the present invention. [Figure 6] FIG. 6 is a schematic diagram depicting the application of a sample to a testing device according to some embodiments described herein. [Figure 7] FIG. 7 is a schematic diagram illustrating the state of a diagnostic test device at the end of its life cycle, i.e., when liquid has migrated through the membrane components of the LFA and into the wick, according to some embodiments of the present invention. [Figure 8] FIG. 8 is a schematic diagram of an exemplary process for analyzing signals obtained from a sensing device, according to some embodiments of the present invention. [Figure 9] FIG. 9 is a schematic diagram illustrating a perspective view of roll-to-roll (R2R) manufacturing of an inspection device including an LFA connected to a PCB via an adhesive substrate according to some embodiments of the present invention. [Figure 10] FIG. 10 is a flow chart of an exemplary process for R2R manufacturing of a testing device according to some embodiments of the present invention. [Figure 11]FIG. 11 is a schematic diagram illustrating an exemplary GUI presented on a smartphone display providing instructions for use and / or test results of a test device including a lateral flow assay connected via adhesive tape to a PCB including a sensor, according to some embodiments of the present invention. [Figure 12A] FIG. 12A is a schematic diagram of an exemplary planar element implemented as a PCB with a resonant magnetometer designed to connect to an LFA via an adhesive substrate, according to some embodiments of the present invention. [Figure 12B] FIG. 12B is a schematic diagram of an exemplary planar element implemented as a PCB designed to connect to an LFA via an adhesive substrate and to interchangeably connect to an exemplary resonant magnetometer, in accordance with some embodiments of the present invention. [Figure 13] FIG. 13 is a graph showing response curves from a reference coil and a test coil over time, as measured by the inventors, in accordance with some embodiments of the present invention. [Figure 14] FIG. 14 is a graph depicting the phenomenon of ions flowing across a coil producing changes to the coil's resonant frequency and calculated inductance as measured by the inventors in accordance with some embodiments of the present invention. [Figure 15] FIG. 15 is a continuation of the curves from the graph of FIG. 13 extending over a longer period of time in accordance with some embodiments of the present invention. [Figure 16] FIG. 16 is a graph calculated by subtracting the normalized inductance of the test coil from the normalized inductance of the reference coil after the test has been run long enough for the inductance to stabilize, in accordance with some embodiments of the present invention. [Figure 17] FIG. 17 is a graph showing the difference in dynamic response between the positive and negative curves of an electromagnetic sensing (EMS) modality used in an inspection device manufactured by the inventors, according to some embodiments of the present invention. [Figure 18]FIG. 18 is a graph comparing electromagnetic data measured using embodiments described herein with colorimetric data measured using standard optical approaches, demonstrating the advantages of electromagnetic sensing (EMS) over optical sensing methods currently used in the lateral flow industry. [Figure 19] FIG. 19 is a schematic diagram of an exemplary inductive sensor configuration and immunosensor assembly used in testing for testing magnetic IL-6 lateral flow strips according to some embodiments of the present disclosure. [Figure 20] FIG. 20 includes standard curves showing the effect of IL-6 concentration on signal readout for two inductive immunosensor compensation schemes used in experiments evaluating testing of magnetic IL-6 lateral flow strips according to some embodiments of the present invention. [Figure 21] FIG. 21 includes time series signal profiles of two inductive immunosensor compensation schemes for test runs at 10 ng / mL IL-6 for IL-6 experiments, according to some embodiments of the present invention. [Figure 22] FIG. 22 shows the averaged truncated time series signal profiles of two inductive immunosensor compensation schemes for all tests performed in the IL-6 experiment, according to some embodiments of the present invention. [Diagram 23] FIG. 23 includes schematic diagrams illustrating top views of the schematic diagrams 604A-604D described with reference to FIG. 6 and corresponding sensor response curves according to some embodiments described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0099] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. In carrying out or testing embodiments of the present invention, methods and materials similar or equivalent to those described herein can be used, but exemplary methods and / or materials are described below. In case of conflict, this patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not necessarily intended to be limiting.

[0100] Some embodiments of the present invention are described herein, by way of example only, with reference to the accompanying drawings. With particular reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for the purpose of illustrative discussion of embodiments of the present invention. In this regard, the description with the drawings will make apparent to those skilled in the art how embodiments of the present invention may be practiced.

[0101] The present invention in some embodiments thereof relates to medical devices, and more particularly, but not exclusively, to medical devices based on lateral flow assays.

[0102] The term analyte binding element as used herein refers to any biological or non-biological reagent that shares a strong and selective affinity with a particular analyte. Examples of analyte binding elements include, but are not limited to, antibodies, recombinant proteins, peptides, enzymes, aptamers, nucleic acids, and molecularly imprinted polymers. Analyte binding elements can selectively bind to specific analytes when interacting with each other.

[0103] An aspect of some embodiments of the present invention relates to a test device for evaluating an analyte. The analyte, if present, is in a liquid sample applied to a lateral flow test element component connected to the test device. The test device includes one or more electronic sensors (sometimes referred to herein as "sensors") disposed on a planar element. The sensor is configured to sense one or more sensing areas of the lateral flow test element for evaluation of the analyte, e.g., a signal output by the sensor is analyzed to determine the presence and / or concentration of the analyte in the sensing area. An adhesive substrate is connected to a surface of the planar element and configured to connect to a surface of the lateral flow test element. The adhesive substrate fixes the sensor in a fixed position relative to the sensing area of ​​the lateral flow test element. When the adhesive substrate is sandwiched between the sensor and the sensing area, the adhesive substrate is selected to have a thickness and / or to be made of a material that allows the sensor to sense the sensing area with a sufficient signal strength to obtain an accurate measurement (e.g., a signal strength above a threshold, a probability of a measurement being made based on a signal above a threshold).

[0104] The test device optionally includes a lateral flow test element, which may be a lateral flow test stand, microfluidic, microarray, or any other test format having a sensing area along a substantially planar interface.

[0105] It should be noted that the sensing region described herein is the region on the lateral flow test element that is being probed by the electronic sensor. The sensing region may include the test region(s) (i.e., where the analyte binding members are present) and / or may include the reference region(s).

[0106] In some embodiments, the test device comprises a planar element having a sensor and an adhesive substrate configured to connect to a surface of the lateral flow test element before the lateral flow test element is connected. In other embodiments, also referred to herein as a test device assembly, the test device comprises an assembly of a planar element, a sensor, an adhesive substrate, and a lateral flow test element.

[0107] The test device described herein may be an all-in-one system, or part of a multi-part system, e.g., a two-part system including a cartridge (i.e., a test device) and a reader designed to collect test signals from the cartridge. The term cartridge may be interchangeable with the term test device. All-in-one and multi-part systems may further communicate with a nearby connected smart device (e.g., a smartphone) to, for example, analyze data collected from the test device and / or display interactive test results from the test device to the user. Multi-part systems, optionally two-part systems, allow a user to reuse at least one component of the system (e.g., a reader) with different disposable cartridges. In some embodiments of a two-part system with a reader, the disposable cartridge is interchangeably connected (e.g., by insertion) to the reader, and the reader collects signals from a sensor on the disposable cartridge. The reader may further transmit signals to an adjacent connected smart device. In some embodiments of an all-in-one system, the test device may communicate directly with the connected smart device, such that the user does not need a reader to receive test results.

[0108] Aspects of some embodiments of the invention relate to systems, methods, apparatus, and / or code instructions (e.g., stored on a data storage device and executable by one or more hardware processors) for the evaluation of an analyte. A signal is obtained from a sensor of a test device to which a liquid sample potentially containing the analyte is applied. Exemplary sensors include capacitive sensors for capacitive sensing and / or inductive sensors for inductive sensing. The sensor(s) are disposed on, within, and / or around a planar element of the test device (e.g., embedded within, disposed on, etc.) for sensing one or more sensing areas of a lateral flow test element to which a liquid sample is applied. The sensing area may include an analyte binding element designed to bind to an analyte in a liquid sample. As used herein, the term "test area" refers to a sensing area that includes an analyte binding element. As used herein, the term "reference area" refers to a portion of a sensing area that is not intended to bind to an analyte. The signal obtained from the test area may be analyzed with reference to the reference area as described herein. The adhesive substrate is connected to the surface of the planar element and the surface of the lateral flow test element, and fixes the sensor in a position facing the area of ​​the lateral flow test element, including the test area and the reference area of ​​the sensing region. The signal is analyzed to measure the selective binding and accumulation of the analyte in the test area of ​​the lateral flow test. Evidence of the presence of the analyte, the amount of bound analyte, the lack of evidence of the presence of the analyte, and / or the concentration of the analyte are determined according to the analysis. Diagnosis and / or prognosis of a medical condition, e.g., infection by an infectious disease agent, can be made according to the detected evidence of the presence of the analyte, the lack of evidence of the presence of the analyte, and / or the concentration of the analyte. For example, it may be displayed on a computing device such as a smartphone. This results in clearly accurate results and avoids potential errors that may otherwise occur during the interpretation of standard lateral flow assays (e.g., a user waiting too long and reading a positive result when the result is actually negative, or missing a faint line, thereby reading a positive result as negative).The outcome may be, for example, a health-related condition, a health state, or a generalized analyte concentration in a sample (e.g., bacteria for assessing food safety). A health state may be, for example, a non-reportable, non-life threatening health condition that does not require diagnosis by a medical professional, classified by various biomarker levels.

[0109] The adhesives described herein ensure proper alignment of the planar element and sensor relative to the lateral flow test element after assembly of the test device (ie bonding the planar element to the lateral flow test element via the adhesive).

[0110] An aspect of some embodiments of the invention relates to a method of manufacturing the test device described herein. The test device may be manufactured using a modification of a roll-to-roll (R2R) manufacturing method (also referred to as reel-to-reel manufacturing). A roll of components for making a plurality of lateral flow test elements is unrolled. A roll of flexible planar elements is unrolled. The roll of flexible planar elements has a plurality of spaced apart sensors disposed thereon. The roll of flexible planar elements may be a flexible printed circuit board (PCB) that integrates and / or connects the sensor(s). An adhesive substrate is laminated onto a surface of the flexible board. The adhesive substrate may be, for example, a roll of unrolled self-adhesive tape, a spray-on adhesive, and / or an adhesive sprayed by a sprayer and / or applied by an applicator. The components for forming the lateral flow test elements are laminated onto the adhesive substrate to form a master assembly. The master assembly is sliced ​​into a number of slices. Each slice represents a respective test device for testing an analyte in a sample applied thereon as described herein.

[0111] At least some embodiments described herein address the technical problem of improving the accuracy of measuring an analyte and / or improving the usability of a test device, optionally a lateral flow test device, for measuring an analyte. At least some embodiments described herein improve the technical field of lateral flow test devices by increasing the accuracy of measuring an analyte and / or by increasing the usability of the test device (e.g., a lateral flow test device). In at least some embodiments, a solution to the technical problem and / or an improvement to the technical field is provided by an electronic sensor located on a planar element of the test device and an adhesive substrate applied to the surface of the planar element for consistency in connecting the area of ​​the lateral flow test element, including the sensing area, facing the electronic sensor. The adhesive substrate fixes the position of the sensor in close proximity to the sensing area, improving the accuracy of the measured signal, for example allowing detection of low concentrations of analyte. When the adhesive substrate is sandwiched between the electronic sensor and the region of the lateral test flow element that includes the sensing region, the height (e.g., thinness) of the adhesive substrate is selected to allow sufficient signal strength of the sensor sensing the sensing region through the adhesive substrate, which improves the sensitivity and / or signal-to-noise ratio of the test device. The height of the adhesive substrate can be minimized. This improvement is in contrast to, for example, colorimetric lateral flow assays that use visual indicators to indicate evidence of the presence of an analyte or lack of evidence of the presence of an analyte. Such lateral flow assays effectively provide a binary result when they are interpreted by the naked eye, indicating evidence of the presence of an analyte or lack of evidence of the presence of an analyte, which indicates a signal below the visual threshold, i.e., making it difficult to determine and / or detect the concentration of the flow analyte that is understandable by eye or by a camera.The sensor, held in place by the adhesive substrate, collects a reliable signal that is translated into a clear and accurate result for the user, avoiding potential errors that may otherwise occur in standard lateral flow assays, such as the user waiting too long and reading a positive result when it is actually negative, or missing a faint line and thereby reading a positive result as negative.

[0112] The performance of electronic measurement devices, such as capacitive or inductive sensors, decreases as the distance between the sensing element and the object and / or environment being probed increases. At least some implementations described herein include an adhesive substrate to reduce the distance between the lateral flow assay and a printed circuit board (PCB) that houses the electronic sensor that senses the sensing region(s) of the lateral flow test element (e.g., probes the flow and / or accumulation of nanoparticles (e.g., in the test region)), as described herein.

[0113] The adhesives described herein ensure proper alignment of the planar element and sensor relative to the lateral flow test element after assembly of the test device (ie bonding the planar element to the lateral flow test element via the adhesive).

[0114] At least some embodiments described herein address the technical problem of manufacturing the test elements described herein. At least some embodiments described herein improve the technology of manufacturing the test elements. In at least some embodiments, a solution to the technical problem and / or an improvement to the technical field is provided by modifying the roll-to-roll manufacturing approach by using a roll of an unfolded flexible planar element having a plurality of spaced apart electronic sensors disposed thereon. The flexible planar element can be a flexible PCB. An adhesive substrate is applied on a surface of the flexible planar board. The adhesive substrate can be a roll of self-adhesive tape that is unfolded on the surface of the flexible planar element. The unfolded roll of components for making a multiplicity of lateral flow test elements is laminated to the adhesive substrate to make a master assembly. The master assembly is then sliced ​​to make individual test devices. This manufacturing method quickly and efficiently produces a multiplicity of test devices.

[0115] At least some implementations of the systems, methods, devices, and / or code instructions described herein address the technical problem of improving the accuracy and / or improving the ease of use of LFAs and / or other point-of-care (POC) testing devices. At least some implementations of the systems, methods, devices, and / or code instructions described herein improve the technology of LFAs and / or POC testing devices by improving their accuracy and / or ease of use.

[0116] LFAs are ubiquitous in the field of rapid diagnostics, with the most common application of this technology being pregnancy testing. Today, LFAs are also used to detect infectious diseases such as COVID-19 and biomarkers such as prostate-specific antigen. Although versatile, LFAs present some drawbacks, particularly surrounding the interpretation and communication of results to the user (e.g., patient). Traditionally, interpretation of LFA results is done qualitatively via a visual signal readout, such as the presence of a line or dot that can be resolved by eye after the test has had a chance to be performed, which typically takes 10-15 minutes. This interpretation method presents challenges for patients with visual impairments, for example, and also makes it difficult to obtain a quantitative result for the concentration of the analyte in question. In addition, false negative results can occur if the analyte concentration is not high enough to produce an observable visual readout to the patient, and false positives can occur if the test is interpreted too long after the sample has been applied.

[0117] In at least some implementations, technical issues with LFAs are addressed and / or improvements in LFA technology are provided by using electronic sensors to optionally perform continuous (or near continuous) electromagnetic sensing (e.g., capacitive, inductive) that are fixed in place by an adhesive substrate for sensing one or more sensing regions. The sensors and / or other electronic components can interface with new and / or existing LFAs to transform the LFA from a qualitative physical inspection to a quantitative digital integration platform. The sensors and / or associated electronic components fixed in place by an adhesive substrate for sensing one or more sensing regions enable one or more of the following:

[0118] - Detecting lower concentrations of analyte does not necessarily result in a detectable signal readout in standard LFAs.

[0119] • A quantitative measurement of the amount of analyte (e.g., concentration) in a sample in contrast to standard LFAs, which typically provide a binary result, i.e., positive or negative.

[0120] • Faster time to results with continuous (or near-continuous) data monitoring allows for positive results to be communicated as soon as there is a statistically significant signal arising from the assay. This enablement contrasts with standard LFAs, where a fixed waiting period is required before results are available.

[0121] ● Electronic results are available, which can be, for example, presented on a client terminal display, stored for future access (e.g., to obtain trends, such as to detect increases or changes in biomarker levels over time that may indicate the emergence of a medical condition), and / or transmitted electronically to others, e.g., health care providers. This feasibility contrasts with standard LFAs, where results are only shown visually on the physical LFA itself. In some LFAs, results are only available for a short window of time, and results displayed after the window are invalid.

[0122] ● Tests that are routinely performed in laboratories and / or by trained professionals can be performed at home. One example is sexually transmitted infections (STIs) such as chlamydia and gonorrhea. In other examples, tests for other infectious diseases or biomarkers can be performed. In yet another example, at least one of cortisol and melatonin for stress and / or sleep monitoring is used. In yet another example, levels of bacteria in food can be checked to ensure safe consumption.

[0123] At least some implementations of the systems, methods, testing devices, and / or code instructions described herein address the technical challenges to improve the sensitivity, limit of detection (LOD), signal-to-noise ratio (SNR), and / or dynamic range of sensor-based lateral flow assays (e.g., of capacitive and / or inductive based sensors (e.g., as described herein)). At least some implementations of the described systems, methods, apparatus, and / or code instructions improve the technical field of sensor-based lateral flow assays.

[0124] At least some implementations of the systems, methods, devices, and / or code instructions described herein address the technical challenge of providing a rapid, simple test for a medical condition, e.g., an infectious disease, that can be performed by a user themselves, such as in a home environment. At least some implementations of the systems, methods, devices, and / or code instructions described herein improve the art of testing for infectious disease diseases and biomarkers. Examples of infectious diseases are sexually transmitted infections (STIs), such as chlamydia and gonorrhea. Other infectious disease diseases and / or biomarkers (e.g., proteins, nucleic acids, hormones, vitamins, bacteria, or viruses) may include those present in food, water, feces, urine, saliva, blood, etc.

[0125] At least some implementations of the systems, methods, devices, and / or code instructions described herein enable widespread infectious disease testing by providing reliable, inexpensive at-home testing solutions, and further optional private and convenient access to telemedicine services. At least some implementations allow testing, diagnosis, and treatment for easily curable infectious diseases (e.g., STIs) all on the same day, while ensuring the quality and reliability patients expect from medical services. At least some implementations described herein allow for the measurement of health-related biomarkers (e.g., cortisol, melatonin, testosterone, progesterone, tetrahydrocannabinol (THC), influenza A, influenza B, group A streptococcus, procalcitonin, C-reactive protein, and Escherichia coli) at home to provide insights into aspects of health and wellness.

[0126] At least some implementations described herein provide an improvement over other approaches for testing for infectious diseases, etc. Standard approaches for testing include receiving testing at a doctor's office, laboratory, and / or send-in testing services. Such standard approaches can take 1-3 weeks to receive results, are costly, require trained personnel to perform, and / or are inconvenient for the patient. In contrast, at least some implementations described herein provide results in about 5-15 minutes and can be used by the patient themselves, e.g., in their own home.

[0127] At least some implementations described herein provide an all-in-one testing solution that augments traditional point-of-care (POC) testing with the addition of a proprietary electronic reader embedded in a single disposable casing.

[0128] At least some implementations described herein provide a two-part system that includes a disposable component (i.e., a testing device as described herein) and a reusable reader component designed to obtain measurements from the disposable component.

[0129] At least some implementations described herein provide users with an affordable, at-home testing solution that allows them to skip clinics and long wait times for results without compromising the quality of their care.

[0130] At least some implementations of the systems, methods, apparatus, and / or code instructions described herein address the technical challenges of manufacturing the inspection devices described herein. At least some implementations of the systems, methods, apparatus, and / or code instructions described herein improve the manufacturing process by providing an approach for manufacturing the inspection devices described herein.

[0131] As used herein, the terms "lateral flow test strip" and "lateral flow test element" are used interchangeably.

[0132] High-throughput manufacturing processes are commonly used for the production of low-cost rapid diagnostics. LFA is a type of paper-based biodetection technology, which is the most popular rapid diagnostic format on the market, mainly due to the inexpensive materials and scalable manufacturing process used to manufacture LFA-based devices. Traditionally, LFAs are manufactured at scale using a roll-to-roll (R2R) manufacturing process, whereby reels of paper-based membranes and other porous materials of the lateral flow test strip, such as sample pads, conjugate pads, test or nitrocellulose pads, and wicks, are unfolded and sequentially placed on a reel of backing cards. The backing cards are generally made from plastics such as polystyrene (PS) or polyvinyl chloride (PVC) laminated with a pressure-sensitive self-adhesive and serve as the main mechanical support of the LFA. The self-adhesive bonds the backing card and the porous components of the LFA during the R2R manufacturing process.

[0133] At least some implementations of the described systems, methods, devices, and / or code instructions provide a scalable approach to manufacturing biosensors as solid-state bioelectrical interfaces that directly integrate embedded conductive elements and other electronics into ubiquitous biodetection technologies. At least some implementations of the described systems, methods, devices, and / or code instructions provide a R2R manufacturing lateral flow strip approach in which a reel of flexible PCB performs the functions that would be performed by a standard backing card on which reels of membrane-based lateral flow strip components are assembled, secured in place using reels of adhesive tape, and cut into individual strips to create individual test devices.

[0134] In at least some embodiments, as described herein, replacing the traditional plastic backing card of a lateral flow strip in an LFA-based biosensor with a flexible PCB offers potential advantages and / or technical improvements, such as: (1) embedding the sensor (e.g., conductive element, planar coil, and / or capacitor) directly into the lateral flow test strip to streamline the manufacturing process; (2) reducing the distance between the sensor (e.g., conductive element, planar coil, and / or capacitor) and the area of ​​interest on the LFA to improve sensor sensitivity; and (3) combining the backing structure and sensor (e.g., conductive element, planar coil, and / or capacitor) of the LFA to reduce material costs while maintaining structural integrity and biosensing functionality.

[0135] At least some implementations of the systems, methods, devices, and / or code instructions described herein address the technical problem of increasing the accuracy, sensitivity, LOD, SNR, and / or dynamic range of a lateral flow assay. At least some implementations of the systems, methods, devices, and / or code instructions described herein improve the technology of lateral flow assays by increasing the accuracy, sensitivity, LOD, SNR, and / or dynamic range. At least some implementations address the technical problem and / or improve the technology based on an electromagnetic sensor located in a PCB that is fixed in place relative to the LFA by an adhesive substrate.

[0136] At least some implementations of the systems, methods, devices, and / or code instructions described herein address the technical problem of providing a simple lateral flow assay designed for use by individuals at home. At least some implementations of the systems, methods, devices, and / or code instructions described herein improve the technology of lateral flow assays by providing a simple lateral flow assay designed for use by individuals at home. At least some implementations are based on an inductive sensor located in a PCB that is fixed in place relative to the LFA by an adhesive substrate. At least some of such implementations provide results to a mobile device, which may be, for example, a user's smartphone.

[0137] Magnetic LFAs differ from their visual or fluorescent counterparts, generally distinguished by the use of magnetic nanoparticles rather than colloidal gold, latex beads, dyes, or other optical detection labels, although in some embodiments the tests are processed similarly and particle accumulation at the test and control lines represents the test result. Magnetic lateral flow readers may identify the presence of extremely low concentrations of nanoparticles accumulated at the test line of the LFA, concentrations that would be impossible or difficult to visualize through conventional optical or fluorescent readers. This could lead to a significant increase in the sensitivity of LFAs, opening the door to the diagnosis, prognosis, and monitoring of infections and biomarkers, including infections and biomarkers that exhibit very low physiological concentrations that are currently undetectable by optical or fluorescent LFAs. At least some implementations described herein are improvements over alternative existing approaches for using magnetic lateral flow assays to measure the accumulation of magnetic nanoparticles at test and control lines, such as giant magnetoresistance (GMR), bridge circuits (e.g., Wheatstone bridges), or resonant magnetometry. Such existing approaches utilizing benchtop readers specific to LFAs are bulky, expensive, and / or not suitable for diagnostics and monitoring at the point of need (PON, i.e., at home). Furthermore, rather than using a system of cameras, lenses, diodes, and filters to detect the presence of nanoparticles at the inspection and control lines, at least some implementations described herein use LFAs in which a backing card (traditionally a physical support for the membrane that constitutes the LFA) may be replaced by a PCB having sensors that are fixed in place relative to specific locations of the LFA using an adhesive substrate, as described herein. Alternatively or additionally, a PCB is added in addition to the backing card, e.g., the PCB is connected to the backing LFA (i.e., the LFA including the backing card) via an adhesive substrate such that the backing card is sandwiched between the PCB and the membrane component of the LFA.

[0138] Before describing at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and arrangement of components and / or methods set forth in the following description and / or drawings and / or examples, as the invention is capable of other embodiments or of being practiced or carried out in various ways.

[0139] The present invention may be a system, a method, and / or a computer program product. The computer program product may include a computer-readable storage medium (or media) having computer-readable program instructions thereon for causing a processor to perform aspects of the present invention.

[0140] A computer-readable storage medium may be a tangible device that can hold and store instructions for use by an instruction execution device. A computer-readable storage medium may be, for example, but is not limited to, an electronic storage device, a magnetic storage device, an optical storage device, an electromagnetic storage device, a semiconductor storage device, or any suitable combination of the foregoing. A non-exhaustive list of more specific examples of computer-readable storage media includes portable computer diskettes, hard disks, random access memories (RAMs), read-only memories (ROMs), erasable programmable read-only memories (EPROMs or flash memories), static random access memories (SRAMs), portable compact disk read-only memories (CD-ROMs), digital versatile disks (DVDs), memory sticks, floppy disks, and any suitable combination of the foregoing. A computer-readable storage medium, as used herein, should not be interpreted as being a transitory signal in itself, such as an electric wave or other freely propagating electromagnetic wave, an electromagnetic wave propagating through a wave guide or other transmission medium (e.g., a light pulse passing through a fiber optic cable), or an electric signal transmitted through a wire.

[0141] The computer readable program instructions described herein can be downloaded into each computing / processing device from a computer readable storage medium or to an external computer or storage device over a network, such as the Internet, a local area network, a wide area network, and / or a wireless network. The network can include copper transmission cables, optical transmission fiber, wireless transmission, routers, firewalls, switches, gateway computers, and / or edge servers. A network adapter card or network interface in each computing / processing device receives the computer readable program instructions from the network and forwards the computer readable program instructions for storage in a computer readable storage medium in each computing / processing device.

[0142] The computer readable program instructions for carrying out the operations of the present invention may be either source or object code written in any combination of one or more programming languages, including assembler instructions, instruction set architecture (ISA) instructions, machine instructions, machine dependent instructions, microcode, firmware instructions, state setting data, or object oriented programming languages ​​such as Smalltalk, C++, and conventional procedural programming languages ​​such as the "C" programming language or similar programming languages. The computer readable program instructions may be executed entirely on the user's computer, partially on the user's computer, as a standalone software package, partially on the user's computer, partially on a remote computer, or entirely on a remote computer or server. In the latter scenario, the remote computer may be connected to the user's computer via any type of network, including a local area network (LAN) or wide area network (WAN), or the connection may be made to an external computer (e.g., via the Internet using an Internet Service Provider). In some embodiments, electronic circuitry including, for example, a programmable logic circuit, a field programmable gate array (FPGA), or a programmable logic array (PLA) may execute computer readable program instructions by utilizing state information of the computer readable program instructions to personalize the electronic circuitry to perform aspects of the invention.

[0143] Aspects of the present invention are described herein with reference to flowchart illustrations and / or block diagrams of methods, apparatus (systems), and computer program products according to embodiments of the invention. It will be understood that each block of the flowchart illustrations and / or block diagrams, and combinations of blocks in the flowchart illustrations and / or block diagrams, can be implemented by computer readable program instructions.

[0144] These computer readable program instructions can be provided to a processor of a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine such that the instructions, executed via the processor of the computer or other programmable data processing apparatus, create means for performing the functions / acts specified in the flowchart and / or block diagram block or blocks. These computer readable program instructions can also be stored on a computer readable storage medium that can direct a computer, programmable data processing apparatus, and / or other device to function in a particular manner, such that a computer readable storage medium having instructions stored therein includes an article of manufacture including instructions that implement aspects of the functions / acts specified in the flowchart and / or block diagram block or blocks.

[0145] The computer readable program instructions may also be loaded onto a computer, other programmable data processing apparatus, or other device to generate a computer-implemented process that executes on the computer, other programmable data processing apparatus, or other device a series of operational steps that are performed on the computer, other programmable data processing apparatus, or other device such that the instructions, executing on the computer, other programmable data processing apparatus, or other device, implement the functions / acts specified in the flowchart and / or block diagram blocks or blocks.

[0146] The flowcharts and block diagrams in the figures illustrate the architecture, functionality, and operation of possible implementations of systems, methods, and computer program products according to various embodiments of the present invention. In this regard, each block in the flowcharts or block diagrams may represent a module, segment, or part of instructions, comprising one or more executable instructions for implementing a specified logical function. In some alternative implementations, the functions described in the blocks may occur out of the order described in the figures. For example, two blocks shown in succession may in fact be executed substantially simultaneously, or may be executed in reverse order depending on the functions involved in the blocks. It should also be noted that each block of the block diagrams and / or flowchart diagrams, as well as combinations of blocks in the block diagrams and / or flowchart diagrams, may be implemented by a dedicated hardware-based system that performs the specified functions or acts, or a combination of dedicated hardware and computer instructions.

[0147] Reference is now made to FIG. 1, which is a block diagram of components of a system 100 for evaluating an analyte, according to some embodiments of the present invention. Reference is also made to FIG. 2, which is a schematic diagram of components for assembling an exemplary test device 250 for evaluating an analyte, according to some embodiments of the present invention. It should be noted that the other components described with respect to FIG. 1 are designed to be used with the test apparatus 250 for testing an analyte, for example, signal acquisition circuitry, battery, wireless (e.g., Bluetooth) data interface, etc., for processing signals. Reference is also made to FIG. 3, which illustrates a process for assembling the test device 250 from components 252, 254, and 256, as described with reference to FIG. 2, according to some embodiments of the present invention. Reference is also made to FIGS. 4A-4B, which are schematic diagrams of electric field lines between sensors of planar elements (e.g., PCBs) of the test device, according to some embodiments of the present invention. Reference is also made to FIG. 5, which is a schematic diagram of a cross section of an assembled test device 250, shown in perspective view 502 and cross section view 504, according to some embodiments of the present invention. Reference is also made to FIG. 6, which is a schematic diagram illustrating application of a sample to the test device 250, according to some embodiments described herein. Reference is also made to Fig. 7 for a schematic diagram 702 showing the state of the diagnostic test device 250 at the end of its life cycle, i.e. when the liquid has migrated through the multiple membrane components of the LFA 252 and into the wick 266 as continued in schematic diagram 604D of Fig. 6, according to some embodiments of the present invention. Reference is also made to Fig. 8, which is a schematic diagram of an exemplary process for analyzing signals obtained from the test device, according to some embodiments of the present invention. Reference is also made to Fig. 9, which is a schematic diagram showing a perspective view of a small portion of a lamination process typical for roll-to-roll manufacturing of a test device including an LFA connected to a PCB via an adhesive substrate, according to some embodiments of the present invention. Reference is also made to Fig. 10, which is a flow chart of an exemplary process for R2R manufacturing of a test device, according to some embodiments of the present invention.See also FIG. 11, which is a schematic diagram showing an exemplary GUI 1102 presented on the display of a smartphone 1104 presenting the use and / or test results of a test device 1106 including a lateral flow assay connected via an adhesive tape to a PCB including a sensor, according to some embodiments of the present invention. See also FIG. 12A, which is a schematic diagram of an exemplary planar element 1202 implemented as a PCB with a resonant magnetometer designed to connect to an LFA via an adhesive substrate, according to some embodiments of the present invention. See also FIG. 12B, which is a schematic diagram of an exemplary planar element implemented as a PCB designed to connect to an LFA via an adhesive substrate and to exchangeably connect to an exemplary resonant magnetometer, according to some embodiments of the present invention. See also FIG. 13, which is a graph showing the response curve from a reference coil 1302 and the response curve from a test coil 1304 over time, according to some embodiments of the present invention, as measured by the inventors. See also FIG. 14, which is a graph depicting the phenomenon of ions flowing across the coil, generating changes to the coil's resonant frequency and calculated inductance, as measured by the inventors, according to some embodiments of the present invention. Reference is also made to FIG. 15, which is a continuation of the curves 1302 and 1304 from the graph of FIG. 13, extending over a longer period of time, according to some embodiments of the present invention. Reference is also made to FIG. 16, which is a graph calculated by subtracting the inductance of the test coil from the inductance of the reference coil after the test has been run long enough for the inductance to stabilize, according to some embodiments of the present invention. Reference is also made to FIG. 17, which is a graph showing the difference in dynamic response between the positive curve 1702 and the negative curve 1704 of the electromagnetic sensing (EMS) modality used in a test device manufactured by the inventors, according to some embodiments of the present invention. Reference is also made to FIG. 18, which is a graph comparing the electromagnetic data 1822 measured using the embodiments described herein with the colorimetric data 1832 measured using a standard optical approach, showing the advantages of electromagnetic sensing (EMS) over the optical sensing methods currently used in the lateral flow industry.FIG. 19 is a schematic diagram of an exemplary inductive sensor configuration and immunosensor assembly used in testing for magnetic IL-6 lateral flow strip testing, according to some embodiments of the present disclosure. See also FIG. 20, which includes standard curves showing the effect of IL-6 concentration on the signal readout of two inductive immunosensor compensation schemes used in experiments evaluating testing of magnetic IL-6 lateral flow strips, according to some embodiments of the present invention. See also FIG. 21, which includes time series signal profiles of two inductive immunosensor compensation schemes for test runs at 10 ng / mL IL-6 in the IL-6 experiment, according to some embodiments of the present invention. See also FIG. 22, which shows the averaged truncated time series signal profiles of two inductive immunosensor compensation schemes for all tests run in the IL-6 experiment, according to some embodiments of the present invention. See also FIG. 23, which includes schematic diagrams showing top views of schematic diagrams 604A-D described with reference to FIG. 6 and corresponding sensor response curves, according to some embodiments of the present invention.

[0148] The system 100 may perform the operations of the methods described with reference to Figures 2 to 23 by a processor 102 of a computing device 104 executing code instructions stored in a memory 106 (also referred to as a program store).

[0149] The system 100 includes a testing device 150 for testing a test material as described herein.

[0150] The test device 150 includes a planar element 156, one or more electronic sensors 152, and an adhesive substrate 158. The test device 150 is designed to connect to a lateral flow test element 160 that includes one or more sensing regions 162 that include analyte binding elements designed to bind to an analyte present in a solution that is applied to the lateral flow test element 160.

[0151] The test device 150 may be designed as a disposable device that is discarded after the liquid sample is applied. Alternatively, the test device 150 may be designed as a disposable cartridge designed to receive a sample and connect to an external reader. Alternatively, the test device 150 may be implemented as an all-in-one system with a built-in reader that may be disposable.

[0152] It should be noted that the inspection device 150 relates to a high-level design having different possible implementations. Further exemplary embodiments are described below, for example with reference to Figures 2, 11, and 12A-12B.

[0153] An adhesive substrate 158 is connected to a surface of the planar element 156 and configured to connect to a surface of the lateral flow test element 160. The adhesive substrate 158 is applied to fix the position and / or orientation of a region of the lateral flow test element 160 including a sensing region 162 that is aligned facing the electronic sensor 152. The sensing region 162 may be aligned and facing the electronic sensor 152.

[0154] The adhesive substrate is spread on the surface of the planar element 156 and on the surface of the lateral flow test element 160. The adhesive substrate 158 may be spread over the area of ​​the lateral flow test element 160 including at least one electronic sensor 152 and / or sensing area 162. Alternatively, or additionally, the adhesive substrate 158 may be spread outside the area of ​​the lateral flow test element 160 including the electronic sensor 152 and / or sensing area 162. The adhesive substrate 158 may be sized to substantially match the size of the surface of the planar element 156 and / or the size of the surface of the lateral flow test element 160, for example at least about 80%, or 90%, or 100%. The planar element may be at least the size of a nitrocellulose membrane.

[0155] The adhesive substrate places the sensing region 162 in close proximity, e.g., about 5-100 micrometers, to the electronic sensor 152. The proximity of the sensor 152 to the sensing region 162 enabled by the adhesive substrate improves the output of the sensor 152 (e.g., higher SNR, more sensitive readings, and other improved measurements described herein).

[0156] The distribution of the adhesive substrate 158 can be selected such that there is no significant amount of air between the sensing area 162 and the electronic sensor 152. Note that there may be a negligible amount of air that does not significantly affect the transmission of signals through the adhesive substrate. An insignificant amount of air is present in the adhesive substrate 158 in continuous contact between the electronic sensor 152 and the sensing area 162. When the adhesive substrate 158 is in contact between the sensor 152 and the sensing area 162, the absence of air between the sensor 152 and the sensing area 162 improves the output of the sensor 152 (e.g., higher SNR, more sensitive readings, and other improved measurements described herein).

[0157] Optionally, the adhesive substrate 158 is implemented as a self-adhesive tape. The adhesive substrate 158 has opposing adhesive surfaces. One surface is connected to the surface of the planar element 156. The opposite adhesive surface is configured to connect to the surface of the lateral flow test element 160.

[0158] Alternatively or additionally, the adhesive substrate 158 includes an adhesive, a tape, or the like.

[0159] The adhesive substrate 158, the planar element 156 and the lateral flow test element 160 may each be elongate elements arranged parallel to one another to form a sandwich structure. The adhesive substrate 158 is sandwiched between a surface of the planar element 156 and a surface of the lateral flow test element 160. The adhesive substrate is sandwiched between the electronic sensor 152 and an area of ​​the lateral flow test element that includes the sensing region 162.

[0160] The height (e.g., thickness) of the adhesive substrate 158 is selected to be thin enough to obtain a signal from the electronic sensor 152 and sensing area 162 strong enough to exceed a threshold for evaluation of the test substance, while at the same time providing sufficient bonding strength to secure the planar element 156 in place against the lateral flow test element 160.

[0161] The sensor 152 is positioned on the planar element 156 at a location selected to measure sufficient signal strength from a sensing region 162 of the lateral flow test element 160 for evaluation of the analyte.

[0162] Optionally, the sensing region 162 includes a test region and a reference region distinct from the test region. Optionally, at least two sensors 152 are provided, a test sensor for sensing the test region and a reference sensor for sensing the reference region. The test region includes an analyte binding element designed to selectively bind to the analyte. The reference region does not include an analyte binding element. An analyte administered to the lateral flow test element 160 flows across the reference region without selectively binding thereto. The test sensor is positioned to sense the test region including an analyte binding element designed to selectively bind to an analyte administered to the lateral flow test element 160. The reference sensor is positioned within the planar element 156 and positioned to sense the reference region. Signals output by the test sensor and / or the reference sensor are analyzed to detect evidence of the presence of the analyte, the concentration of the analyte, and / or the absence of evidence of the presence of the analyte, as described herein.

[0163] The analyte binding elements of sensing region 162 are designed to selectively bind to and detect an analyte, e.g., a biomarker for assessing the presence of a medical condition in a subject, such as an infectious disease biomarker for assessing whether the subject is infected with an infectious disease. Examples of infectious disease biomarkers include markers for sexually transmitted diseases (e.g., gonorrhea, chlamydia), as well as markers for COVID-19 (also known as SARS-CoV-2 and coronavirus). Other examples of analytes that the analyte binding elements of sensing region 162 are designed to bind include health-related biomarkers for assessment of relevant health conditions, such as cortisol (e.g., for stress monitoring), melatonin (e.g., for assessment of sleep), testosterone, interleukin-6 (IL-6) (e.g., for systemic inflammation), progesterone (e.g., for assessment of fertility), levels of bacteria in food to ensure safe consumption, tetrahydrocannabinol (THC) (e.g., for screening for drug users), influenza A, influenza B, group A streptococcus (e.g., for screening for infectious diseases), procalcitonin, C-reactive protein (e.g., for systemic inflammation), and Escherichia coli (e.g., food safety). The analyte may be, for example, saliva, urine, blood, etc., such as salivary cortisol and / or blood-based cortisol.

[0164] The sensor 152 may be designed to generate an electromagnetic field having magnetic field lines that originate from the sensor 152, pass through the adhesive substrate 158, pass through the sensing area 162, pass back through the adhesive substrate 158, and return to the sensor 152. The magnetic field lines may originate from one portion of the sensor 152 and terminate at another portion of the sensor 152. The magnetic field lines may originate and terminate at the same portion of the sensor 152, for example, as described herein with reference to Figures 4A-4B. Note that the electric field lines in capacitive sensing shown in Figure 4A are not the same as the magnetic field lines in inductive sensing shown in Figure 4B.

[0165] The sensor 152 may be implemented as one or more capacitive sensors for capacitive sensing and / or one or more inductive sensors for inductive sensing. A capacitive sensor may include an interdigitated arrangement of one or more pairs of electrodes. The inspection device 150 may include circuitry designed to operate the inductive sensor at its resonant frequency.

[0166] In implementations using inductive sensing, the testing device 150 may include a controller operating at a sampling frequency to measure a change in the resonant frequency of the sensor 152 indicative of binding of an analyte to at least one sensing region. The resonant frequency of the sensor 152 may be selected based on the physical design of the sensor 152. Exemplary resonant frequencies of the sensor 152 may be within the range of, for example, about 1-50 megahertz (MHz), or 0.001-40 MHz, or 1-10 MHz, or 5-10 MHz, or other values. Labels selected to exhibit superparamagnetic properties may be used to identify the presence of an analyte by an inductive sensor.

[0167] The surface of the planar element 156 is dimensioned to correspond at least to the surface of the lateral flow test element 160. The surface of the planar element 156 may be as large as the surface of the lateral flow test element 160, or may be larger, such that the entire surface of the lateral flow test element 160 is connected to the planar element 156.

[0168] The planar element 156 serves as a physical support for the components of the lateral flow test element 160. When standard lateral flow test elements are used where a backing card is traditionally used, the planar element 156 may replace the backing card entirely in some embodiments. In other embodiments, the planar element 156 may be attached to the backing card via an adhesive substrate 158. The planar element 156 may be implemented as a PCB, with the sensor 152 integrated within and / or connected to the PCB.

[0169] The test region of the sensing region 162 of the lateral flow test element 160 comprises an analyte binding element designed to selectively bind to an analyte of interest, if present in a sample administered to the lateral flow test element, as described herein. The sensing region is not necessarily the same as the test region. In some embodiments, the detection region is different from the test region. In some embodiments, the detection region is the same as the test region.

[0170] The testing device 150 may include a data interface 154, e.g., a transceiver, antenna, wireless interface, wired interface, virtual interface, for providing the output of the sensor 152 to another computing device 104 for analyzing the signal to detect the presence of an analyte. The reader components described herein with respect to a two-part system may be implemented by the computing device 104. Alternatively, in a single component system, the testing device 150 may be in communication with the computing device 104.

[0171] The lateral flow test element 160 may be, for example, a lateral flow assay in which a solution flows through the lateral flow test element by capillary action.

[0172] In some embodiments, a lateral flow test element 160 (also referred to herein as an LFA) is designed using a sandwich assay format. This configuration of the LFA 160 has analyte binding elements patterned on the test area, which bind to analytes present in a sample as the sample flows through the test area. At the same time, a label (e.g., a nanoparticle) functionalized with a complementary analyte binding element also binds to the analyte captured in the test area. Taken together, these binding events result in the accumulation of analyte-label complexes in the test area.

[0173] In some embodiments, the lateral flow test element 160 is designed using a competitive assay format. This assay format is preferred for small molecule targets such as hormones and vitamins, where steric hindrance makes it unlikely that two biorecognition elements will bind to one analyte. In this format, the LFA 160 has the analyte patterned on the test area prior to application of the sample. If little or no analyte is present in the sample, the label will bind to the analyte present in the test area and generate a strong signal. If a sufficient concentration of analyte is present in the sample, the majority of the label will bind to the analyte in the sample instead of the analyte patterned on the test area. Once this occurs, the label typically cannot bind to the analyte on the test line, and therefore the signal from the test area decreases as the concentration of analyte in the sample increases. This differs from the sandwich assay format, where more analyte in the sample typically results in a larger test area signal due to greater analyte-label accumulation.

[0174] It should be noted that the design of the LFA 160 is not necessarily limited to the designs discussed above, as combinations of the designs and / or other designs may be implemented.

[0175] The computing device 104 obtains data output by one or more electronic sensors 152 of the testing device 150, optionally via a data interface 154. The computing device 104 analyzes the signals output by the electronic sensors 152 to obtain a result, for example, positive or negative for a particular biomarker (e.g., indicative of an infectious disease), a diagnosis (e.g., for an infectious disease), and / or an amount of the biomarker (e.g., a concentration value, and / or within a range).

[0176] The computing device 104 may be implemented, for example, as one or more and / or combinations of a group of connected devices, a client terminal, a server, a virtual server, a computing cloud, a virtual machine, a desktop computer, a thin client, a network node, and / or a mobile device (e.g., a smartphone, a tablet computer, a laptop computer, a wearable computer, a glasses computer, and a watch computer).

[0177] Numerous architectures of the apparatus 100 based on the computing device 104 can be implemented. For example, architectures designed to provide local services. The computing device 104 can be implemented as a standalone device (e.g., a kiosk, a client terminal, a smartphone) that includes locally stored code instructions 106A implementing one or more of the operations described with respect to Figs. 2-23. The locally stored instructions can be obtained, for example, from another server by downloading the code over a network and / or by loading the code from a portable storage device. The computing device 104 can obtain the signal output by the sensor 152 of the inspection device 150, optionally via a network 110, such as a short-range wireless connection and / or a cable connection (e.g., USB). The computing device 104 locally analyzes the signal, for example, by feeding the signal to a machine learning model 114A and / or applying a set of rules, such as thresholds. The results (e.g., test results and / or diagnosis) may be provided for presentation on the display 120 of the particular user's computing device 104 and / or forwarded to the server 112 to enable another user to obtain the results, e.g., a healthcare provider and / or public health agency server may obtain assistance from a physician.

[0178] In another example, the architecture is designed to provide centralized services. The computing device 104 executing the stored code instructions 106A may be implemented as one or more servers (e.g., network server, web server, computing cloud, virtual server) that provide centralized services (e.g., one or more of the operations described with respect to Figs. 2-23) to one or more client terminals 108 via the network 110. Each client terminal 108 is locally connected to a respective inspection device 150 via the network 110 and / or another connection, such as a short-range wireless connection, a cable (e.g., USB), etc. The computing device 104 may provide, for example, software as a service (SaaS) to the client terminals 108, software services accessible using a software interface (e.g., application programming kit (API), software development kit (SDK)), applications for local download to the client terminals 108, add-ons to a web browser executed on the client terminals 108, and / or the ability to use a remote access session to the client terminals 108, such as via a web browser executed by the client terminals 108 accessing a website hosted by the computing device 104. Signals acquired by each client terminal 108 from each sensor 152 of each testing device 150 are provided to a computing device 104 via one or more of the techniques described above. The computing device centrally analyzes each signal, for example by feeding the respective signals to a machine learning model 114A and / or applying a set of rules (e.g., thresholds), and provides a result (e.g., a diagnosis) to the respective client terminal 108 (e.g., for presentation on a display) and / or to a server 112, such as a healthcare provider and / or public health authority.

[0179] It should be noted that the ML model 114A may be trained on the training data 114B as described herein. The training may be performed by the computing device 104 and / or by another device that provides the trained ML model 114A to the computing device 104.

[0180] The hardware processor 102 of the computing device 104 may be implemented as, for example, a central processing unit (CPU), a graphics processing unit (GPU), a field programmable gate array (FPGA), a digital signal processor (DSP), and an application specific integrated circuit (ASIC). The processor(s) 102 may include a single processor or multiple processors (homogeneous or heterogeneous) arranged for parallel processing, as a cluster, and / or as one or more multi-core processing devices.

[0181] The memory 106 stores code instructions executable by the hardware processor 102, e.g., random access memory (RAM), read only memory (ROM), and / or storage devices, e.g., non-volatile memory, magnetic media, semiconductor memory devices, hard drives, removable storage devices, and optical media (e.g., DVD, CD-ROM). The memory 106 stores code 106A that, when executed by the hardware processor(s) 102, implements one or more features and / or operations of the methods described with reference to Figures 2-23. The memory 106 may store other data, e.g., test identification (ID) associated with batch-specific calibration data.

[0182] The computing device 104 may include a data storage device 114 for storing data, e.g., machine learning models 114A and / or other code for analysis of signals (e.g., sets of rules, thresholds) as described herein, and / or a training data repository 114B including data for training the ML models 114A, and / or GUI code 114C for providing an interactive display for presenting results of tests on a user's client terminal and / or for establishing a communication session with a remote entity such as a healthcare provider. The data storage device 114 may be implemented, for example, as a memory, a local hard drive, a virtual storage device, a removable storage unit, an optical disk, a storage device, and / or as a remote server and / or a computing cloud (e.g., accessed using a network connection).

[0183] The network 110 may be implemented, for example, as the Internet, a local area network, a virtual network, a wireless network, a cellular network, a local bus, a point-to-point link (eg, wired), and / or a combination of the above.

[0184] The computing device 104 may include a network interface 116 for connecting to the network 110. The network interface 104 and / or the network interface 116 of the data interface 154 of the inspection device 150 may be implemented, for example, as one or more of a network interface card, a wireless interface for connecting to a wireless network, a physical interface for connecting to a cable for network connectivity, a virtual computing device implemented in software, network communications software providing a higher layer of network connectivity, and / or other implementations. It should be noted that the network interface 116 may connect to the data interface 154 of the inspection device 150 without necessarily going through the network 110 and / or via another connection, e.g., a short-range wireless connection and / or a cable.

[0185] The computing device 104 uses a network 110 (or another communication channel, such as a direct link (e.g., wired, wireless) and / or an indirect link (e.g., via an intermediate computing unit, such as a server, and / or via a storage device)) to communicate:

[0186] *For example, a remote server 112 of a healthcare provider and / or public health agency. A communication session may be established between the client terminal 108 and / or the computing device 104 and / or the server 112 to provide, for example, a remote medical consultation regarding the results.

[0187] *The client terminal 108 provides the features and / or operations described herein when the computing device 104 is implemented as a server that remotely provides those functions and / or operations.

[0188] * The data interface 154 of the inspection device 150 acquires the data output by the sensor 152 .

[0189] The computing device 104 and / or client terminal 108 include and / or are in communication with one or more physical user interfaces 120 that include and / or include mechanisms for a user to input data (e.g., request a remote medical consult) within a GUI (e.g., generated based on GUI code 114C) and / or view displayed results (e.g., diagnose). Exemplary user interfaces 120 include, for example, one or more of a touch screen, a display, a gesture activation device, a keyboard, a mouse, and voice software activated using a speaker and microphone.

[0190] 8, instructions can be presented, for example, on a display of a mobile instrument and / or other computing device, prior to starting an assay (analysis), at 802. The instructions can request that the user connect their mobile device (e.g., smartphone) to the test device, for example, via an in-app prompt.

[0191] At 804, a connection between the mobile device and the inspection device may be established, for example, using a short-range wireless connection (e.g., Bluetooth® low energy) and / or other short-range connection technology. The inspection device may be powered, for example, by wireless charging via a user's interaction with the mobile device and / or by a small battery.

[0192] At 806, once a connection is established, assay readings are collected on the test device, and the readings may be continuously streamed (and / or intermittently transmitted) to a nearby connected smart device via a wireless protocol such as Bluetooth® low energy. In some embodiments, the communication electronics are embedded on the test device directly adjacent to the sensor. In other embodiments, the communication electronics and / or other circuitry is separate from the test device.

[0193] The data does not necessarily have to be stored on the device. A memory chip may be included, but the data may be streamed in real time from the start of the test. Thus, the data may be structured as a multi-dimensional time series, with each test signal including thousands of test and reference sensor sample readings taken over the duration of the test.

[0194] At 808, a signal is acquired from a sensor of the inspection device as described herein. The signal may be acquired by a computing device (e.g., a smartphone), optionally via a network connection over a network, such as a short-range, temporarily established wireless connection.

[0195] As described herein, a signal may be obtained when liquid is applied and / or before liquid is applied, after liquid is applied to the testing device and the liquid flows over a sensing area facing the sensor (e.g., drawn by capillary action).

[0196] The signal may be obtained from a capacitive sensor for capacitive sensing and / or an inductive sensor for inductive sensing.

[0197] The signal is obtained from a sensor sensing a sensing region of the lateral flow test element. The sensing region includes an analyte binding member designed to bind to an analyte administered to the lateral flow test element. The signal may indicate the concentration of the analyte and / or evidence of the presence of the analyte or lack of evidence indicating the presence of the analyte binding to the analyte binding member.

[0198] The signal may be further calculated and / or obtained from signals output by a test electronic sensor sensing the test region and a reference electronic sensor sensing the reference region. The reference region is separate and spaced apart from the sensing region. Analytes that selectively bind to the analyte binding elements in the test region do not selectively bind to the reference region. Analyte binding elements are not present in the reference region.

[0199] If a sufficient concentration of the analyte is present in the sample, the resulting signal (e.g., generated by the nanoparticles) is expected to be of sufficient signal strength (e.g., above a threshold) to detect the presence of the analyte based on the proximity of the sensor to the sensing area provided by the adhesive substrate, which provides the proximity by being connected to a surface of the planar element and to a surface of the lateral flow test element, as described herein, to immobilize the electronic sensor in a position facing the area of ​​the lateral flow test element that contains the sensing area.

[0200] At 810, the signal is analyzed to measure the accumulation of the analyte in the sensing region of the lateral flow test element. Analysis of the signal may be performed locally by a computing device (e.g., a smartphone) and / or remotely by a server in communication with the computing device (e.g., the signal is transmitted to the server via the computing device).

[0201] Once the assay has been performed and the relevant data streamed to an associated reading device (e.g., a smartphone, an external reader, or part of an all-in-one architecture), the mobile device begins to process the data to confirm the presence of the analyte.

[0202] As used herein, the term "reader" or "reading apparatus" refers to a reader component that may be incorporated into an all-in-one system (i.e., a testing device) or may be included as part of a multi-part system.

[0203] There are one or more exemplary approaches for analyzing the data:

[0204] *Take the readings against the standard curve.

[0205] *Analytical transforms and filters are performed on the signals to improve diagnostic accuracy. These include, but are not limited to, frequency-space transformations, curve fitting, direct analysis, etc.

[0206] *The smart device application can store a machine learning model trained to classify signals based on the test scenario. This machine learning model can be trained on time series data collected from labeled samples with known concentrations of analytes. This training can be done in a laboratory setting, resulting in parametric weighting of the architecture of the machine learning (ML) model before being stored on the smart device. Notably, this ML model is created such that the user's test processing can be performed entirely on-device, without communication with a remote server. While the ML model can use custom frameworks to achieve a positive outcome in each specific test scenario, it is based on modern time series analysis processes developed and open-sourced by multiple contributors in the AI ​​community.

[0207] The signal may be analyzed by feeding the signal to an ML model, e.g., a classifier, a statistical classifier, one or more neural networks of various architectures (e.g., convolutional, fully connected, deep, encoder-decoder, iterative, graph, combination of multiple architectures), a support vector machine (SVM), logistic regression, k-nearest neighbors, decision tree, boosting, random forest, regressor, etc. The ML model may be trained on a training dataset using a supervised and / or unsupervised approach. The ML model may be trained on a training dataset including records, each record including a sample signal labeled with at least one ground truth indicator of the presence of the analyte, the absence of evidence indicating the presence of the analyte (e.g., the absence of the analyte, the absence of a sufficient concentration of the analyte), and the concentration of the analyte.

[0208] The signals may be analyzed using other approaches, such as a set of rules, mathematical equations, and / or other deterministic approaches.

[0209] At 812, the presence of the analyte and / or the concentration of the analyte is determined according to the analysis. The absence of the presence of the analyte can be determined according to the analysis. The absence of the presence of the analyte can be due to the absence of the analyte or the absence of a sufficient detectable concentration of the analyte.

[0210] At 814, a diagnosis of the medical condition of the analyte is determined according to evidence of the presence of the analyte, the concentration of the analyte, and / or the absence of evidence of the presence of the analyte.

[0211] A diagnosis can be made, for example, when the analyte is present, when the analyte is not detected, when the concentration of the analyte is above a threshold, and when the concentration of the analyte is below a threshold, For example, lack of detection of the analyte can be used to rule out a medical condition, for example, to ensure that the user is not infected with an infectious agent.

[0212] The medical condition can be, for example, an infection by an infectious disease agent, such as COVID-19, or an STI, such as chlamydia, or gonorrhea.

[0213] Optionally, once a test is performed, there can be two possible outcomes. First, the test is invalid. An invalid test can result from a failure mode, e.g., use of an expired test device, reuse of a previously used test device, and / or technical issues with components of the test device (e.g., sensor, integrated circuit, flow of liquid sample through the test strip). In this case, an automated attempt is made to understand the error and the problem is communicated directly to the user in the app. It is recommended to perform additional tests. Second, in the case of a valid test, the user is provided with the user's outcome via the interface of the application on the user's smart device. In some embodiments this can be in the form of a positive vs. negative diagnosis for a single or multiple infections, and in other embodiments the detected concentration of a key biomarker. In the case of a disease or infection determined by concentration rather than the presence of the test substance, the user is presented with the relevant information.

[0214] At 816, in response to a valid test result, a communications session may be established with the remote client terminal of the healthcare provider and / or public health entity, such as a video call, a chat session, a voice call, etc.

[0215] Alternatively or additionally, when a user is provided with a valid test result corresponding to a diagnosis of a health condition, the application can utilize location services or user-entered data to verify the region in which the test is being performed. Given this information, the application can determine if compliance with local health authorities is required. The application can report the condition, such as a reportable disease, while anonymizing as much information as permitted under the jurisdiction. Concurrent with the diagnosis, the user may be given access to telehealth services as well as expertly verified learning materials. Given the appropriate geographic context, telehealth services can communicate the test results via API integration to provide the user with appropriate care, including but not limited to remote care and medication prescriptions.

[0216] At 818, a treatment that is effective for treating the medical condition may be prescribed to a user (e.g., a patient) by a health care provider in response to the communication session and / or may be automatically generated in response to a diagnosis, for example.

[0217] The treatment may be, for example, a prescription for an antibiotic to treat a sexually transmitted disease.

[0218] Reference is now made again to Figure 2, which is a schematic diagram of components for assembling an exemplary test device 250 for the evaluation of an analyte, according to some embodiments of the present invention. The test device 250 is assembled from a lateral flow assay 252 (also referred to herein as a lateral flow test element), an adhesive substrate 254, and optionally an elongated planar element 256. The test device 250 may be implemented based on the test device 150 described with reference to Figure 1.

[0219] The LFA 252 may include the following components, which may be standard: a sample pad 260, a conjugate pad 262, a test pad (e.g., nitrocellulose (NC) membrane, synthetic paper) 264, and a wick 266. A standard LFA is physically supported by a semi-rigid plastic structure called a backing card. The LFA 252 may be a standard LFA without a standard backing card (e.g., the backing card has been removed, the backing card has not been assembled), also referred to herein as an unbacked LFA.

[0220] The adhesive substrate 252 may be a few tens of microns thin, such as KN2211 adhesive from Kenosha Tapes, or in other embodiments may be thinner than 10 μm, such as an ultra-thin PET-based 5 μm double-sided tape (No. 5600) from Nitto Denko.

[0221] Planar element 256 may be implemented as a printed circuit board (PCB). PCB 256 may replace a standard backing card and provide physical support for LFA 252. PCB 256 includes sensors 270, which may be capacitive and / or inductive sensors. Sensors 270 may include, for example, test sensors 274 and reference sensors 272, as described herein.

[0222] An adhesive substrate 252 bonding the PCB 256 to the LFA 252 enables precise collection of sensor measurements (eg, capacitive and / or inductive data) at specific preselected locations of the LFA 252, optionally in real time.

[0223] Attention is now directed back to Fig. 3, which illustrates the assembly of an inspection device 250 from components 252, 254, and 256, as described with respect to Fig. 2, according to some embodiments of the present invention. Schematic 302 illustrates an adhesive substrate 254 connected to a PCB 256, and an unbacked LFA 252 that is not yet connected to the adhesive substrate 254. The LFA 252 is aligned with the adhesive substrate 254, which is connected to the PCB 256, to position the LFA 252 relative to a sensor in the PCB 256. In particular, the inspection line 290 of the LFA 252 is secured to the PCB 256 by the adhesive substrate 254 at a location above and / or near the sensor 270, as described herein. Schematic 304 illustrates a fully assembled inspection device 205, assembled from components 252, 254, and 256, as described herein.

[0224] Turning now to Figures 4A-4B, which are schematic illustrations of electromagnetic field lines between sensors on a planar element (e.g., a PCB) of an inspection device, according to some embodiments of the present invention, Figures 4A-4B show the importance of an adhesive substrate fixing the position of the sensors on the PCB relative to specific regions of the unbacked LFA, as described herein.

[0225] FIG. 4A shows electric field lines 402A passing between electrodes 404A and 406A implemented as a planar capacitor. Although one capacitor is shown, it should be understood that more than one capacitor may be implemented. The sensors 404A and 406A are disposed on a planar element 450 of the test device. The planar element 450 may be implemented as a PCB board as described herein. The electrodes 404A and 406A, such as planar capacitors, are disposed along a plane. Such a planar arrangement of the electrodes 404A and 406A differs from a parallel plate capacitor setup, in which the electrodes are disposed on either side of the material whose capacitance is to be probed. The electric field lines 402A leave the plane in which the electrodes 404A and 406A reside, travel upward in an arcuate path, pass through the adhesive film 408 and nitrocellulose membrane 410 (or other implementation for a test pad) of the test device, probe the capacitance of the adhesive film 408 and nitrocellulose membrane 410, and then return to the other electrode 404A or 406A.

[0226] 4B shows magnetic field lines 402B generated by coil traces (called traces) 404B and 406B implemented as a planar inductive sensor. Traces 404B and 406B are disposed on a planar element 450 of a testing device. Planar element 450 may be implemented as a PCB board as described herein. Electric field lines 402B pass through planar element 450, adhesive film 408, and nitrocellulose film 410 of the testing device, probing the inductance of planar element 450, adhesive film 408, and nitrocellulose film 410.

[0227] Reference is now made again to Figure 5, which illustrates a schematic diagram of an assembled inspection device 250 shown in perspective view 502 and cross-section view 504 of cross-section 506, according to some embodiments of the present invention. Figure 5 illustrates the importance of the adhesive substrate 254 in fixing the location of the sensor on the PCB relative to a particular area of ​​the unlined LFA, as described herein. The inspection device 250 and its components are as described herein, such as in Figures 2-3.

[0228] The signal generated by the LFA may be optically resolved, for example, as the appearance of visible light over the duration of the test, caused by the accumulation of nanoparticle labels in the test line 290. In capacitive sensor embodiments described herein, the nanoparticle labels may be metallic (e.g., gold, silver, iron, etc.). Inductive sensors may use magnetic nanoparticle labels (e.g., iron oxide, magnetite, etc.). Achieving alignment between the test line 290 and the sensor (e.g., the centerline of the long axis of the sensor aligned with and facing the centerline of the long axis of the test line 290), obtained and secured by the adhesive substrate 254, maximizes the interaction between the electromagnetic field lines of the sensor and the volume in which the nanoparticles will be immobilized in the context of a visual signal output, as indicated by the test line 290, as described herein with reference to Figures 4A-4B.

[0229] LFA 252 is designed to allow the flow of a sample fluid containing an analyte of interest through a series of overlapping membranes that have been treated with specific chemical and biological reagents, i.e., components 260, 262, 264, and 266. These reagents allow for the movement of the sample and analyte, as well as the capture of the analyte at a specific physical location along the test pad 264. The location where a signal can be visually interpreted based on the accumulation of nanoparticle labels can be delineated by the development of an optical readout (e.g., colorimetric or fluorescent) at a test line 290 that can appear over time. Test line 290 is set to be aligned with test sensor 274. To the left of test sensor 274 is a reference (or ref) sensor 272 that is placed near test sensor 274 and used as a negative control against which the response of test sensor 274 over the duration of the assay can be compared to determine a positive or negative result based on the accumulation of nanoparticles.

[0230] Attention is now directed back to FIG. 6, which is a schematic diagram illustrating the application of a sample to an inspection device 250, according to certain embodiments described herein.

[0231] Schematic diagram 602 illustrates the application of a biological fluid sample 600 to test device 250. The biological fluid sample 600 contains an analyte that is likely to be of interest for the particular example of diagnostic tester 250. The biological fluid sample 600 is applied to sample pad 260. The sample matrix and sample volume will vary depending on the application.

[0232] Schematics 604A-D show the flow of sample 600 through LFA 252. The porous membrane of the LFA, when wetted, allows liquid movement by capillary action. Flow lines 624A-E provide a cross-sectional representation of how far liquid sample 600 has moved along testing device 260 relative to schematics 604A-D.

[0233] Schematic 604A shows liquid sample 600 moving from sample pad 260 to conjugate pad 262 where nanoparticles conjugated to detection molecules wait.

[0234] Diagram 604B shows the fluid wetting the test pads 264 over both sensors 270 (e.g., capacitors and / or inductors 272, 274). The fluid moves faster than the analyte-label complex through the porous membrane, and the areas over the reference 272 and test 274 sensors become saturated with the liquid sample.

[0235] Diagram 604C shows analyte-label complexes beginning to accumulate at test line 290 above test sensor 274. Analyte binding elements patterned on test pad 264 above test sensor 274 cause complexes to accumulate, but such complexes do not selectively bind onto reference sensor 272.

[0236] Schematic 604D shows the liquid sample being absorbed by the wick 266. The highly absorbent material that comprises the wick 266 forms a fluid sink, allowing movement of the sample volume across the sensor 270.

[0237] Attention is now directed to FIG. 7, which is a schematic diagram 702 shown as the state of diagnostic test device 250 at the end of its life cycle, i.e., when liquid has migrated through the multiple membrane components of LFA 252, as follows from schematic diagram 604D of FIG. 6, according to some embodiments of the present invention. The accumulation of nanoparticles in the capture region above test sensor 274 resulted in an optically resolvable signal consisting of an optical readout (e.g., colorimetric or fluorescent) at test line 290. Thus, the volume of test pad 264 above test sensor 274 gradually develops different dielectric properties due to the accumulation of nanoparticles when compared to the remainder of test pad 264, including the volume directly above reference sensor 272. This accumulation process is monitored by periodically probing the capacitance, in the case of a capacitive sensor, or inductance, in the case of an inductive sensor, of the material at a particular selected frequency (e.g., about 1-50 Hertz (Hz)) over the entire duration of the test, allowing one to distinguish the differences in the time series capacitance / inductance curves generated by test 274 and reference 272 sensors. These differences allow for the differentiation of positive and negative results electronically and without the need to rely solely or at all on visual signal output. For example, for assays performed by a user with extremely high concentrations of analyte in its applicable biological matrix, the accumulation of analyte-label complex at test line 290 may be significant enough to confirm a positive result prior to the appearance of any resolvable visual signal. Exemplary potential advantages of the embodiments and / or implementations described herein include higher sensitivity, faster time to result, improved device usability, and / or automated interpretation of results.

[0238] Attention is now directed to Figure 11, which is a schematic diagram illustrating an exemplary GUI 1102 presented on a display of a smartphone 1104 presenting instructions for use and / or test results for a test device 1106 including a lateral flow assay connected via adhesive tape to a PCB including a sensor, according to some embodiments of the present invention. The GUI 1102 may present instructions, test results, and / or options for establishing a communications session with a healthcare provider, for example, as described with reference to Figure 8.

[0239] Attention is now directed to FIG. 9, which is a schematic diagram illustrating a perspective view of roll-to-roll manufacturing of an inspection device including an LFA connected to a PCB via an adhesive substrate, according to some embodiments of the present invention.

[0240] A reel of backing structure 906 (e.g., PCB) containing sensor 970 is laminated with a self-adhesive reel 904 (also referred to herein as adhesive tape) and is laminated sequentially with reels of sample membrane 910, conjugate membrane 912, test membrane 914, and wicking membrane 916 to form a master assembly and aid in proper overlap for function of the LFA.

[0241] Alternatively, or in addition, in other embodiments, reels of cover tape as well as other LFA components may be stacked onto a reel of backing structure 906, and the reels of membrane-based components 910, 912, 914, and 916 may be modified and / or removed depending on the LFA-based biosensor of interest.

[0242] A portion of the test membrane 914 is patterned with capture lines 980 immobilized along the length of the test membrane 914. The capture lines 980 include analyte binding elements, e.g., antibodies, aptamers, and / or enzymes, which are selected based on their affinity for at least one particular analyte of interest. The capture lines 980 are not necessarily visible to the naked eye prior to application of the fluid sample, but are shown for reference. The capture lines 980 may be visualized to ensure proper alignment on the sensor using a dye such as Orange G, which may dissolve as fluid flows through the strip and should not affect the functionality of the analyte binding elements or the optical properties of the test.

[0243] The reels of membrane-based components 910, 912, 914, and 916 are stacked sequentially on the reel of backing structure 906 at one end of the assembly. Individual lateral flow strips 952, representing individual diagnostic test devices, are then cut from the master assembly at equal intervals 930. The stacking may be done by sandwiching a self-adhesive tape between the planar element and the components of the test device. The test devices may be cut from the same end where the stacking is finished. The master assembly may be transferred from the lamination device to a reel-feed guillotine for cutting. The lateral flow strips 952 may be cut from the master assembly using an automated guillotine to improve accuracy and repeatability during the strip cutting process.

[0244] Lateral flow strip 952 comprises a backing structure 956, a self-adhesive layer 954, a sample pad 960, a conjugate pad 962, a test pad 964, a wicking pad 966, and a test line 990 (line 990 does not have to be a test line, but can be a control line or other type of line to provide quality control), which share the same composition as the reel of backing structure 906, the self-adhesive reel 904, the reel of sample membrane 910, the conjugate membrane 912, the test membrane 914, the wicking membrane 916, and the capture line 980, respectively.

[0245] The reel of backing structure 906 may include a flexible PCB, typically constructed from polyimide. The sensor 970 may be constructed from metal traces, typically made from copper, etched onto the reel of backing structure 906. The reel of self-adhesive 904 is typically constructed from an adhesive less than 100 microns thick, typically including a layer of polyester sandwiched between two layers of acrylic adhesive.

[0246] In this embodiment, there may be two pairs of sensors 970 on each lateral flow strip, with the sensor pair in the test sensing area comprising sensors 972 and 974 and the sensor pair in the compensation or reference sensing area comprising sensors 976 and 978. Each pair of sensors 970 may include a test sensor and a reference sensor. The test sensor 974 in the sensor pair in the test sensing area may be aligned, and optionally centered, over a test line 990 on the lateral flow strip 952. The alignment may be such that the test sensor 974 faces the test line 990.

[0247] The test sensor 974 and the reference sensor 972 in the test sensing area are used to measure changes in local properties of the lateral flow strip 952 at the test line 970 due to accumulation of captured analyte-label complexes. If the sensor 970 (i.e., each sensor) comprises one or more planar coils with at least one layer designed to measure changes in inductance, the label may comprise iron oxide nanoparticles. The sensors 976 and 978 are used to measure changes in local properties of the lateral flow strip 952 due to sample flow, non-specific binding of the label and analyte-label complexes, or environmental factors. Measurements from the sensors 976 and 978 in the compensation area can serve as a reference to improve the accuracy and reproducibility of measurements from the sensors 972 and 974 in the test sensing area.

[0248] Sensors 970 may be added, removed, or modified depending on the particular requirements of the LFA-based biosensor of interest, including in other embodiments the number of analytes to be detected, the need for a quantitative, semi-quantitative, or qualitative result readout, or the sample matrix to be tested. Sensor pairs are not absolutely necessary, as only one sensor is needed to measure a signal, although additional sensors can improve the performance of the testing device.

[0249] In different embodiments, other electronic components and circuits such as analog to digital converters, operational amplifiers, antennas, and traces connecting these components may be assembled or etched onto the reel of backing structure 906 or may be connected to the lateral flow strips 952 from an external reader following the R2R manufacturing process.

[0250] Returning now to Figure 10, which is a flow chart of an exemplary process for R2R manufacturing of an inspection device, according to some embodiments of the present invention. The inspection device is, for example, as described herein with reference to Figures 1 and 2. The process of R2R manufacturing of the inspection device is visually illustrated with reference to Figure 9.

[0251] As used herein, the terms "roll" and "reel" are interchangeable.

[0252] At 1002, a roll of flexible planar element is unfolded. The roll of flexible planar element includes a plurality of spaced apart electronic sensors disposed thereon. The flexible planar element may be implemented as a flexible PCB.

[0253] At 1004, an adhesive substrate is laminated onto a surface of a flexible planar element.

[0254] The adhesive substrate may be embodied as a roll of self-adhesive tape. The roll of adhesive tape is unrolled. The unrolled self-adhesive tape is laminated onto the surface of the flexible planar element.

[0255] Alternatively or additionally, the sticky substrate may be implemented as an adhesive, which may for example be sprayed by a sprayer and / or deposited by a nozzle and / or applied by an applicator.

[0256] At 1006, a roll of components for making a plurality of lateral flow test elements is unfolded and stacked.

[0257] At 1008, all of the components for making the lateral flow test element are laminated to an adhesive substrate to create a master assembly.

[0258] The processes described with reference to 1002, 1004, 1006, and / or 1008 may be performed substantially simultaneously such that the rolls are unwound, layered, and stacked in a substantially parallel fashion.

[0259] At 1010, the master assembly is sliced ​​into multiple slices, each slice representing a respective test device for assessing the presence of an analyte in a sample applied thereon.

[0260] Slicing may be performed across the width of the master assembly so that there are the same number of test sensors and reference sensors on each inspection device.

[0261] Each test device comprises a planar element of the roll of flexible planar elements, one or more electronic sensors of the roll of flexible planar elements, and an adhesive substrate connected to a surface of the planar element and to a surface of the lateral flow test element for fixing the electronic sensor in a position facing a sensing area that includes analyte binding elements designed to bind to an analyte administered to the lateral flow test element.

[0262] Reference is now made again to Figures 12A and 12B, which show schematic diagrams of a resonant magnetometer with an exemplary planar element implemented as a PCB and designed to connect to an LFA via an adhesive substrate, according to some embodiments of the present invention. Figure 12A shows an all-in-one system with an exemplary planar element 1202A. Figure 12B shows a two-part system with an exemplary planar element 1202B and an exemplary external reader 1270B.

[0263] The exemplary planar element 1202A is implemented as a disposable PCB. The long rectangular region 1204A (also called the lateral flow assay contact region) containing the coil 1206A outlines the location of the lateral flow assay, which may be attached directly to the PCB via a thin layer of adhesive and / or manufactured using a R2R manufacturing approach, as described herein. The PCB 1202A includes one or more of the exemplary regions and components, such as a connection region 1210A for power supply, e.g., a disposable battery, a rechargeable battery, and / or a wireless charging module; a low energy communication module 1212A for transmitting test results (e.g., Bluetooth) to another device (e.g., a user's smartphone); an analog-to-digital converter (ADC) 1214A; the lateral flow assay contact region 1204A; and a coil 1206A, which in different embodiments may serve as a combination test coil and reference coil.

[0264] The exemplary planar element 1202B is implemented as a disposable PCB that can be interchangeably connected to a reusable exemplary external reader 1270B. A long rectangular region 1204B including a coil 1206B outlines the location of a lateral flow assay that can be attached directly to the PCB via a thin layer of adhesive and / or manufactured using a R2R manufacturing approach as described herein. The PCB 1202B includes a lateral flow assay contact region 1204B; a coil 1206B that can function as a combination test coil and reference coil in different embodiments; and a mating contact pad 1250B designed to form a connection to a mating contact pin 1252B of an exemplary connector 1260B of the exemplary reader 1270B. The external reader 1270B includes one or more of the following exemplary areas and components: a connection area 1210B for a power source, e.g., a rechargeable battery; a connector 1256B for power and / or data communication (e.g., a USB-C port); a low energy communication module 1212B for providing test results (e.g., Bluetooth®) to another device (e.g., a user's smartphone); mating contact pins 1252B, and an ADC 1214B.

[0265] In some embodiments, the resonant magnetometer LFA readers described herein are based on the principle of resonant frequency. The coils may be implemented as a stack of four coils of conductive material (e.g., copper, called a four-layer coil) connected in series. The coils may alternatively or additionally be connected in parallel. Each coil may include more or fewer layers and / or turns. The particular design of the coils may be selected for optimization of a particular application.

[0266] The coil receives an AC current modulated by an inductive sensor at a frequency that matches the coil's resonant frequency. This frequency is variable and is a function of the coil's structure, shape, and / or the electromagnetic fields in the environment surrounding the coil. The frequency at which the coil resonates is then computationally converted to an inductance measurement, digitized, and then passed to a processor for signal collection, processing, and / or interpretation. Changes in the electromagnetic environment (e.g., magnets and / or extraneous signals) and / or the coil's approach and / or contact with a physical object (i.e., a lateral flow assay membrane) result in a change in the coil's resonant frequency, which is probed, for example, at a rate of 16 times per second with 28-bit resolution, or other value. Changes in the coil's resonant frequency over time are monitored. The changes provide information about the state of the assay, for example, to determine the presence of an analyte therein.

[0267] The test pad membrane is brought into contact with the coil by a thin adhesive substrate, which keeps the membrane in a fixed position during testing and is also responsible for getting the membrane as close as possible to the coil, since if further testing is to be performed the signal will decay rapidly.

[0268] As discussed in the "Examples" section below, the inventors observed signal changes even in the absence of nanoparticles migrating through the test pad membrane and across the coil. The inventors discovered that the liquid wetting the test pad membrane, as well as the environmental conditions in direct contact with the coil, change the properties of the material, which contributes somewhat to the inductance change. The inventors also observed that many of the samples and buffers passing through the LFA are ionic, e.g., phosphate buffered saline has a salt ion concentration of over 150 mM, and the movement of these ions across the coil through the membrane is probed by the sensor, resulting in a change in the resonant frequency and calculated inductance of the coil.

[0269] The run time of a lateral flow assay is highly variable and can depend on a number of factors, such as the material selected, the viscosity of the sample matrix (e.g., saliva can flow slower than urine), the dimensions of the test device, and the relative humidity and temperature within the casing. After stability has been determined, based on the inventor's knowledge (based on experimentation) that a result can be reliably measured after the inductance of both coils has stabilized, the relative values ​​of the coils are analyzed to determine, for example, whether a sufficient amount of magnetic nanoparticles have accumulated on the test line, or the concentration quantified, for the test to be considered a positive result, as described in additional detail in the "Examples" section below.

[0270] In the inductive sensing embodiment, the inventors have recognized (based on experiments) that the size of the nanoparticles is important and is selected accordingly. After conducting experiments using iron oxide nanoparticles with sizes ranging from 10 to 500 nanometers, the inventors have discovered that superparamagnetic behavior is a key factor in achieving high quality, reproducible results. For iron oxide or magnetite nanoparticles, superparamagnetic behavior is generally observed when the particle size is less than 16 nanometers, otherwise they are in the ferromagnetic domain. This occurs because, to achieve the superparamagnetic regime, the nanoparticles should ideally contain a magnetic monodomain. This phenomenon can only occur for very specific sizes of nanoparticles, at least for iron oxide and magnetite, i.e., in the range of 10-14 nm, but there are others. For example, larger clusters of superparamagnetic nanoparticles with an average total diameter of 100-300 nm show improved signal readout due to the additive properties of the many monodomains of the cluster. At sizes above 16 nm, iron oxide or magnetite nanoparticles are unlikely to exhibit magnetic monodomains, and each individual domain will behave differently due to temperature and environmental electromagnetic noise. This realization is in contrast to assuming, for example, that the magnetic field of the coil (and therefore the calculated inductance of the coil) is most affected when the mass of magnetite or iron oxide is maximized.

[0271] In some embodiments, based on the ability to monitor the flow of liquid through the LFA (e.g., as described herein) and across the coil, and / or the ability to detect when the flow of liquid has stopped, a control line may not be necessary.

[0272] Referring again now to Figure 23, schematic diagram 2304A corresponds to schematic diagram 604A of Figure 6, schematic diagram 2304B corresponds to schematic diagram 604B of Figure 6, schematic diagram 2304C corresponds to schematic diagram 604C of Figure 6, and schematic diagram 2304D corresponds to schematic diagram 604D of Figure 6. The reader is requested to refer back to Figure 6 while considering Figure 24. Signal versus time graphs 2308A-D show the progression of the response curve 2310 for the corresponding schematic diagrams 2304A-D, which shows the difference over time between the signal of the reference coil and the test coil for each corresponding schematic diagram 2304A-D.

[0273] Diagram 2304A shows liquid sample 600 moving from sample pad 260 to conjugate pad 262, where nanoparticles conjugated to detection molecules wait. Because the sample does not wet either the reference or test areas on the reference and test sensors, respectively, the response curve 2310 remains relatively constant.

[0274] Schematic diagram 2304B shows liquid sample 600 wetting test pad 264 over reference sensor 272. Wetting of reference sensor 272 by sample 600 in front of test sensor 274 causes a rapid increase 2312 in response curve 2310, which is due to a substantially equivalent change in the local material properties (e.g., dielectric constant, for capacitive and inductive sensing) of the reference area measured by the reference sensor while the response of the test sensor remains relatively constant. A peak 2314 in response curve 2310 occurs when liquid sample 600 is aligned with reference sensor 272 and completely wets the opposing portion of test pad 264.

[0275] Schematic diagram 2304C shows liquid sample 600 wetting the test pad 264 above the test sensor 274 and analyte-label complexes beginning to accumulate at the test line 290 above the test sensor 274. Wetting of the test sensor 274 by the liquid sample 600 causes a rapid decrease 2316 in the response curve 2310, which cancels the signal resulting from the flow of the liquid sample 600. A reference point 2318 in the response curve 2310 occurs when the liquid sample 600 completely wets the portion of the test pad 264 that is aligned and faces the test sensor 274. The analyte binding elements patterned on the test pad 264 above the test sensor 274 cause accumulation of analyte-label complexes, but such complexes do not selectively bind onto the reference sensor 272. Accumulation of the complexes on the test sensor 274 results in a proportional increase 2320 in the response curve 2310.

[0276] Schematic diagram 2304D shows the liquid sample 600 being absorbed by the wick 266. Once the majority of the sample fluid 600 has passed through the LFA and is absorbed by the wick 266, the change in the response curve 2310 due to the accumulation of analyte-label complexes plateaus indicating the completion of the test. The plateau may occur due to saturation of binding sites on the test line 290 with analyte-label complexes or a decrease in the flow of the sample fluid 600 as the bulk of the sample is absorbed by the wick 266. The signal readout 2322 is measured as the difference in signal intensity of the response curve 2310 between the reference point 2318 and the completion of the test. In an actual embodiment of the test device 250, the signal of a fully wetted sensor prior to analyte label accumulation may not be equivalent to the signal of the sensor prior to wetting. Depending on the placement and configuration of the test and reference sensors, the accumulation of analyte-label complexes may be indicated by an increase or decrease in the signal intensity of the response curve.

[0277] The signal readout can be used to determine the presence or amount (eg, concentration) of the analyte in the liquid sample.

[0278] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental and / or computational support in the following examples.

[0279] example Reference is now made to the following examples, which together with the above descriptions demonstrate some non-limiting embodiments of the invention.

[0280] The inventors have conducted experiments based on at least some of the implementations described herein.

[0281] The inventors have now described a first experiment in which they evaluated the signal from a magnetic inductance coil implementation of the sensor in a sensing device as described herein.

[0282] Attention is now directed to Figure 13, which is a graph showing response curves from a reference coil 1302 and a test coil 1304 over time, as measured by the inventors, in accordance with some embodiments of the present invention. Over the time interval, the membrane above the coils is gradually immersed with the liquid sample. Peaks 1314 and 1318 in response curves 1302 and 1304 correspond to the times when the front of the liquid sample reaches the center of each respective coil.

[0283] Time zero indicates when sample was added to the LFA sample pad, and information gleaned from such a graph can inform about the outcome of the assay. For the data used to generate the graph in FIG. 14, no nanoparticles were added to the test strip, only buffer. We found signal changes even in the absence of nanoparticles moving across the coil, albeit with the nitrocellulose membrane. We found that the liquid bathing the nitrocellulose membrane changes the properties of the material, as well as the environmental conditions in direct contact with the coil, which contribute somewhat to the inductance change. We also found that many of the samples and buffers passing through the LFA are ionic, for example, phosphate buffered saline has a salt ion concentration of over 150 mM, and the movement of these ions across the coil through the membrane is probed by the sensor, resulting in a change in the resonant frequency of the coil and the calculated inductance.

[0284] Attention is now directed to FIG. 14, a graph depicting the phenomenon of ions flowing across the coil producing changes to the coil's resonant frequency and calculated inductance as measured by the inventors, according to some embodiments of the present invention. Two tests were performed in which the strip was first wetted with H2O. Then, around the 2 minute mark, a drop (about 10 microliters (μL)) of PBS was added to the strip and allowed to move. The resulting increase in signal is due to the movement of charge present in the buffer, curve 1402 showing the inductance of H2O over time, and curve 1404 showing the inductance of H2O followed by the addition of PBS over time. An additional 10 μL of H2O was added about 7 minutes to push the PBS through the membrane, which is shown as the downward trend in test 1404 beyond 7 minutes. The slight disturbance in the signal readout of both tests around 2 and 7 minutes is due to the addition of 10 μL of additional fluid to the LFA in both tests.

[0285] Attention is now directed to FIG. 15, which is a continuation of curves 1302 and 1304 from the graph of FIG. 13, extending over a longer period of time, in accordance with some embodiments of the present invention. The test strips used in the experiments were run with an appropriate buffer solution. The strips used did not have nanoparticles applied to them, as in FIG. 14. The signal stabilized at about 50 minutes after addition of the buffer, which is the time 1502 when the inductance signal substantially stabilized, indicating nearly identical flow / wetting conditions across the test and reference sensing elements.

[0286] After time 1502, at approximately the 50 minute mark, the difference in inductance between the test coil curve 1304 and the reference coil curve 1302 is relatively small compared to the difference earlier in the life cycle of the test. If nanoparticles and the corresponding analyte were present in the assay, the presence of the nanoparticles at the test line would have increased the inductance of that coil compared to the reference which would have represented a measurable signal output.

[0287] Attention is now directed to Fig. 16, which is a graph calculated by subtracting the inductance of the test coil from the inductance of the reference coil after running the test long enough for the inductance to stabilize, in accordance with some embodiments of the present invention. The graph of Fig. 16 includes a first line 1622 and a second line 1624 calculated based on data collected over a first trial and a second trial, respectively, on different days, with five data points collected for each trial. A linear regression (R 2 ) indicates the reproducibility of the results.

[0288] Attention is now directed to FIG. 17, which is a graph showing the difference in dynamic response between the positive 1702 and negative 1704 curves of an electromagnetic sensing (EMS) modality used in a test device manufactured by the inventors according to some embodiments of the present invention. The distinction between curves 1702 and 1704 is first visible at about 96 seconds after application of the sample to the test. At approximately this point, the dynamic signal shows an inflection point, after which the accumulation of nanoparticle labels at the test line can be resolved both electromagnetically and optically (in this case). As nanoparticle labels accumulate at the test line over time, the inductance of the sensor measuring a positive test continues to increase, while the inductance stabilizes for a negative test. This difference in behavior, as well as the magnitude and rate of signal increase, can be used in conjunction with the calibration curve of FIG. 16 and the like, to determine and quantify the amount of analyte present in the sample.

[0289] Attention now turns back to FIG. 18, which is a graph comparing electromagnetic data 1822 measured using an embodiment described herein with colorimetric data 1832 measured using a standard optical approach, illustrating the advantages that electromagnetic sensing (EMS) has over optical sensing methods currently used in the lateral flow industry. Typically the signal-to-noise ratio (SNR) of optical sensing techniques falls below the limit of detection when there are between 100 million and 1 billion colorimetric labels present in the test area, which in the case of the experiment used to obtain the colorimetric data 1832 are colloidal gold nanoparticles with a diameter of 15 nanometers (nm). Using existing approaches, optical sensing modalities, be they smartphone cameras, photodiodes, or another type of optical capture technology, are unable to resolve the colorimetric line consisting of less than about 100 million colorimetric labels on a lateral flow test. This means that if the concentration of the analyte is low but is nevertheless present in the sample, there may be hundreds of millions of capture events at the test line, but the assay will still report a false negative.

[0290] Next, a second experiment conducted by the present inventors will be described.

[0291] In this experiment, we present a test device prototype and data processing protocol for the measurement of magnetic IL-6 test strips based on the embodiments described herein. We demonstrate a limit of blank (LOB) of 0.41 ng / mL of IL-6 obtained by the embodiments described herein.

[0292] The primary objective of this experiment was to verify the sensitivity and dynamic range of the test device prototype based on the embodiments described herein using magnetic IL-6 lateral flow test strips. In addition to determining these important immunosensor characteristics, this experiment also served to explore various data processing protocols for interpreting the time series signal profiles collected from the test device prototype, including different sensor compensation schemes and analysis techniques to improve the signal-to-noise ratio (SNR) of the embodiments described herein.

[0293] Attention is now directed back to Figure 19, which is a schematic diagram of an exemplary inductive sensor configuration and immunosensor assembly used in testing for testing magnetic IL-6 lateral flow strips, according to some embodiments of the present invention. Schematic 1902 is an exploded view of the inductive sensor configuration and immunosensor assembly, including sample pad 1960, test pad 1964, and wick 1966, as well as magnetic IL-6 test strip 1952 with administration line 1991 and test line 1990, adhesive substrate 1954, and flexible PCB backing 1956 with coil 0 (C0) 1978, coil 1 (C1) 1976, coil 2 (C2) 1974, and coil 3 (C3) 1972. Schematic 1904 shows a magnetic IL-6 test strip 1952 connected to a flexible PCB backing 1956 via an adhesive substrate 1954 and positioned such that C0 and C2 are aligned with and face control line 1991 and test line 1990, respectively.

[0294] To perform the experiment, IL-6 samples were prepared by diluting the IL-6 control to the desired concentration in 40 μL of running buffer (1X PBS, 0.5% Brij 98, 0.5% BSA). Magnetic nanoparticles (MNPs) were added to the IL-6 sample, followed by 5 μL of anti-IL-6-biotin stock solution. Samples were incubated at room temperature for 5 minutes before being applied to the test strips.

[0295] To collect measurements from the test device, a magnetic test strip was attached to a flexible PCB backing with their control and test lines located over the coil of the sensor, as shown in schematic 1904 of FIG. 19. Once the strip was securely attached to the flexible PCB backing, the test device prototype was activated using the peripheral electronic hardware to begin collecting time series measurements. Following activation of the test device, 50 μL of the desired sample preparation was applied to the sample pad of the attached test strip and allowed to sit for 15 minutes. Time series measurements were collected approximately 16 times per second throughout each 15 minute test period.

[0296] To compensate for changes in environmental conditions within and between tests, induction measurements collected from the test line coil C2 were referenced against measurements collected simultaneously from adjacent coils C1 and C3. The numbered coils are shown in schematic 1902 of FIG. 19. A reference coil was placed over an unpatterned segment of the test pad that is not intended to selectively bind to MNPs, as shown in schematic 1904 of FIG. 19. In this experiment, two main compensation schemes were evaluated that consisted of subtracting the signal of different reference coils from the test coil signal, as follows: C3-C2 (C32) and C1-C2 (C12). A four-parameter logistic regression model was fitted to the standard curves of each compensation scheme.

[0297] Attention is now directed to Figure 20, which includes standard curves showing the effect of IL-6 concentration on the signal readout of two inductive immunosensor compensation schemes used in experiments evaluating the testing of magnetic IL-6 lateral flow strips, according to some embodiments of the present invention. Curves 2022A and 2022B are standard curves for the C32 and C12 compensation schemes, respectively. The signal readout of the standard curve was measured at approximately 13000 data points (i.e., approximately 13 minutes after sample administration).

[0298] All error bars indicate the standard deviation of the tests in triplicate. The operating range of the C32 compensation scheme shown in curve 2022A (i.e., the difference between the upper and lower limits of each curve) is 1.23 times larger than the operating range of the C12 scheme shown in curve 2022B. Furthermore, the average standard deviation of C32 is only 1.05 times larger than that of C12, suggesting that the signal magnitude (i.e., operating range) is not directly proportional to the measurement variation observed across the two compensation schemes.

[0299] The variability in the measurements is likely due to human error during the testing process. For example, in each compensation scheme, the standard deviation of triplicates run at 30 ng / mL had an abnormally large standard deviation, which may have been caused by positioning or placement errors of the strip during testing, which resulted in variations in the alignment or adhesive contact of the aligned and opposing test lines on C2.

[0300] Although compensation schemes C32 and C12 both showed an LOD of 3 ng / mL of IL-6, they showed different LOBs of 0.41 and 0.53 ng / mL of IL-6, respectively. LOB approximations were calculated using a four-parameter logistic regression model and were 3.3 times the standard deviation at 0 ng / mL for each standard curve. This experiment conclusively shows that our test device prototype has the potential to generate highly sensitive tests for the detection and quantification of health-related biomarkers in a point-of-care environment.

[0301] Based on the embodiments described herein, each test performed with the inventors' test device prototype produces a time series profile of inductive measurements from a planar coil on a flexible PCB backing 1956 adhered to a test pad 1964.

[0302] Attention is now directed to FIG. 21, which includes time series signal profiles of two inductive immunosensor compensation schemes for a test run at 10 ng / mL IL-6 for the IL-6 experiment, according to some embodiments of the present invention. Curves 2108A and 2108B are exemplary time series signal profiles for the C32 and C12 compensation schemes, respectively. The profiles for both of these compensation schemes have distinct local patterns, called features, that appear regardless of the concentration of analyte through each test. Each feature is localized to a single point from the time series profile known as a feature point. The feature points are used as a reference to standardize measurements across different tests. Any test that does not contain these feature points can be considered invalid, but none of the tests in this experiment deviated from their expected profile.

[0303] Based on the method of data processing presented here, each compensation profile has two characteristic points: a global extremum and a zero point. As shown by triangles 2114A and 2114B in Fig. 21, the global extremums of the C32 and C21 methods are the minimum and maximum values, respectively. The zero point is more difficult to define, but is generally considered to be the first local extremum after the global extremum of the profile, and is shown by circle 2118A for C32 and circle 2118B for C21 in Fig. 21. The signal readouts 2122A and 2122B are measured as the difference in signal amplitude between the zero point and the end of the time series signal.

[0304] Attention is now directed to FIG. 22, which shows averaged truncated time series signal profiles of two inductive immunosensor compensation schemes for all tests performed in the IL-6 experiment, according to some embodiments of the present invention. Graphs 2208A and 2208B show their zero-truncated time series signal profiles for the C32 and C12 compensation schemes, respectively. Time series signal profiles 2200A and B, 2201A and B, 2211A and B, 2213A and B, 2221A and B, 2223A and B, 2233A and B show tests performed at 0, 0.1, 1, 3, 10, 30, and 300 ng / mL, respectively. Each profile is an average of three runs. The C32 profile shown in 2208A shows a slight dip over the first 1-2 minutes of tests performed with lower concentrations of IL-6 (0-10 ng / mL). Otherwise, most of the profiles in FIG. 22 show a characteristic logarithmic trend reflecting MNP accumulation at the test line.

[0305] The description of various embodiments of the present invention is presented for illustrative purposes, but is not intended to be exhaustive or limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terms used in this specification are selected to best explain the principles of the embodiments, practical applications or technical improvements to the technology found in the market, or to enable those skilled in the art to understand the embodiments disclosed herein.

[0306] It is expected that many related LFAs will be developed during the life of this application and the maturation of the patent, and the scope of the term LFA is intended to include, a priori, all such new technologies.

[0307] As used herein, the term "about" refers to ±10%.

[0308] The words "comprise," "include," "have," and their conjugates mean "including, but not limited to." This term encompasses the terms "consisting of" and "consisting essentially of."

[0309] The phrase "consisting essentially of" means that a composition or method may include additional components and / or steps, but only if the additional components and / or steps do not materially alter the basic and novel characteristics of the claimed composition or method.

[0310] As used herein, the singular forms "a," "an," and the like include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" can include a plurality of compounds, including mixtures thereof.

[0311] The word "exemplary" is used herein to mean "serving as an example, instance, or illustration." Any embodiment described as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments, and / or does not exclude the incorporation of features from other embodiments.

[0312] The term "optionally" is used herein to mean "provided in some embodiments and not provided in other embodiments." Any particular embodiment of the invention may include multiple "optional" features unless such features are inconsistent.

[0313] Throughout this application, various embodiments of the present invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity, and should not be construed as an inflexible limitation on the scope of the present invention. Thus, the description of a range should be considered to have all possible subranges specifically disclosed, as well as individual numerical values ​​within that range. For example, the description of a range such as 1-6 should be considered to have specifically disclosed subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, as well as individual numbers within that range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0314] Whenever a numerical range is given herein, it is meant to include any recited numbers (decimals or integers) within the given range. The phrase "range" between a first and a second designation number is used interchangeably herein and means to include the first and the second designation numbers, and all decimals and integers therebetween.

[0315] It is understood that certain features of the invention that are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination, or as appropriate, in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperable without those elements.

[0316] While the present invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, the present invention is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and broad scope of the appended claims.

[0317] It is the intention of the applicants that all publications, patents, and patent applications mentioned herein are incorporated herein by reference in their entirety as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application should not be construed as an admission that such reference is available as prior art to the present invention. To the extent section headings are used, they should not be construed as necessarily limiting. In addition, any priority documents of this application are incorporated herein by reference in their entirety.

[0318] Related Applications This application claims priority to U.S. Provisional Patent Application No. 63 / 280,191, filed November 17, 2021, the contents of which are incorporated by reference herein in their entirety.

Claims

1. 1. A test device for evaluating at least one test substance, comprising: A planar element; at least one electronic sensor arranged on said planar element for sensing at least one sensing area of ​​the lateral flow test element to evaluate at least one said analyte; an adhesive substrate connected to a surface of the planar element and configured to connect to a surface of the lateral flow test element; 2. An inspection device comprising:

2. The adhesive substrate is spread on the surface of the planar element and configured to spread on the surface of the lateral flow test element. The testing device of claim 1 .

3. the adhesive substrate includes a first adhesive counter surface and a second adhesive counter surface; the first adhesive counter surface is connected to the surface of the planar element; the second adhesive counter surface is configured to connect to the surface of the lateral flow test element; The testing device of claim 1 .

4. The adhesive substrate is selected from the group consisting of adhesives, tapes, self-adhesives, and spray adhesives; The testing device of claim 1 .

5. The lateral flow test element further comprises: The testing device of claim 1 .

6. the adhesive substrate positions at least one of the sensing areas in proximity to at least one of the electronic sensors; 6. The testing device of claim 5.

7. the distribution of the adhesive substrate is selected to exclude a large amount of air from being present between at least one of the sensing areas and at least one of the electronic sensors; 6. The testing device of claim 5.

8. The adhesive substrate is sandwiched between the surface of the planar element and the surface of the lateral flow test element.

6. The testing device of claim 5.

9. the adhesive substrate is sandwiched between at least one of the electronic sensors and an area of ​​the lateral flow test element that includes at least one of the sensing areas; 6. The testing device of claim 5.

10. the adhesive substrate is disposed at least over the at least one electronic sensor and the at least one sensing area; a region of the lateral flow test element including at least one of the sensing regions is aligned with and faces at least one of the electronic sensors; 6. The testing device of claim 5.

11. at least one of the sensing regions of the lateral flow test element comprises an analyte binding element designed to bind to at least one of the analytes administered to the lateral flow test element; 6. The testing device of claim 5.

12. the planar element replaces the backing card of the lateral flow test element, acting as a physical support component for the lateral flow test element; 6. The testing device of claim 5.

13. a thickness of the adhesive substrate is selected to be thin to obtain a sufficiently strong signal above a threshold from the at least one electronic sensor sensing the at least one sensing area for evaluation of the at least one analyte; The testing device of claim 1 .

14. The surface of the planar element has a size at least the size of the surface of the lateral flow test element; The testing device of claim 1 .

15. the planar element includes a printed circuit board (PCB); At least one of the electronic sensors is connected to the printed circuit board and is integrated with the printed circuit board. The testing device of claim 1 .

16. and at least one second electronic sensor disposed on the planar element for sensing at least one reference area of ​​the lateral flow test element that is substantially free of analyte binding members; At least one of the analytes administered to the lateral flow test element flows across at least one of the reference regions without substantially selectively binding to the reference region. The testing device of claim 1 .

17. a signal output by the at least one second electronic sensor sensing the at least one second region is analyzed to assist in measuring the at least one analyte; 17. An inspection device according to claim 16.

18. At least one of the sensing regions includes an inspection region and a reference region different from the inspection region; the at least one electronic sensor comprises a test electronic sensor arranged on the surface-area element for sensing the test area and a reference electronic sensor arranged on the surface-area element for sensing the reference area; The testing device of claim 1 .

19. At least one of the sensing regions includes an analyte binding element designed to bind to at least one analyte corresponding to a biomarker of an infectious disease to assess the presence of an infectious disease in a user. The testing device of claim 1 .

20. The infectious disease biomarkers include markers for at least one of a sexually transmitted disease and COVID-19.

20. The testing device of claim 19.

21. At least one of the sensing regions includes an analyte binding element designed to bind to at least one of the analytes corresponding to a health-related biomarker for assessing a relevant health condition in a user. The testing device of claim 1 .

22. The health-related biomarker is selected from the group consisting of cortisol, melatonin, testosterone, and progesterone.

22. The testing device of claim 21.

23. at least one of the electronic sensors is designed to generate an electromagnetic field that follows electric field lines originating from the at least one of the electronic sensors, passing through the adhesive substrate, passing through the at least one of the sensing areas, passing back through the at least one of the adhesive substrates, and returning to the at least one of the electronic sensors; The testing device of claim 1 .

24. The sensing device of claim 1 , wherein the at least one electronic sensor comprises at least one capacitive sensor for capacitive sensing.

25. Each capacitive sensor includes an interdigitated pair of electrodes.

25. An inspection device according to claim 24.

26. The at least one electronic sensor includes at least one inductive sensor for inductive sensing. The testing device of claim 1 .

27. Each inductive sensor includes at least one planar coil having at least one layer; 27. An inspection device according to claim 26.

28. and further comprising a circuit configured to operate at least one of the inductive sensors at a resonant frequency.

27. An inspection device according to claim 26.

29. a controller configured to operate at a sampling frequency and measure a change in the resonant frequency of at least one of the electronic sensors indicative of binding of at least one of the analytes to at least one of the sensing areas.

29. An inspection device according to claim 28.

30. the resonant frequency of at least one of the electronic sensors is in the range of 0.001 to 40 megahertz (MHz); 30. The testing device of claim 29.

31. a label selected to exhibit superparamagnetic properties is used to identify the presence of at least one of said analytes; 27. An inspection device according to claim 26.

32. and a transmitter configured to transmit a signal sensed by at least one of the electronic sensors to an external computing device for analysis of the signal to determine the presence of at least one of the analytes. The testing device of claim 1 .

33. the test device is implemented as a disposable device designed to be discarded after a liquid sample has been applied to the lateral flow test element; the liquid sample flows by capillary action through the lateral flow test element to a wick, and at least one of the analytes, when present in solution, binds to an analyte binding element in at least one of the sensing regions; The testing device of claim 1 .

34. 1. A computer-implemented method for evaluating at least one test substance, comprising: receiving a signal obtained from at least one electronic sensor of the sensing device; At least one said electronic sensor is arranged on a planar element of the test device for sensing at least one sensing area of ​​a lateral flow test element; at least one of the sensing regions comprises an analyte binding element designed to bind to at least one of the analytes administered to the lateral flow test element; an adhesive substrate is connected to a surface of the planar element and to a surface of the lateral flow test element for fixing at least one of the electronic sensors in a position facing an area of ​​the lateral flow test element containing at least one of the sensing areas; analyzing a signal to measure accumulation of at least one of said analytes in at least one of said sensing areas of said lateral flow test element; determining at least one of evidence indicative of the presence of the at least one analyte, a concentration of the at least one analyte, and evidence indicative of the absence of the at least one analyte; Computer-implemented method.

35. the at least one electronic sensor is selected from the group consisting of at least one capacitive sensor for capacitive sensing and at least one inductive sensor for inductive sensing; 35. The computer-implemented method of claim 34.

36. At least one of the analytes is detected; at least one of the analytes is not detected; the concentration of at least one of the analytes is above a threshold value; the concentration of at least one of the test substances is below the threshold value; determining at least one of a diagnosis, prognosis, or trend of a medical condition, or an analysis of a health condition; 35. The computer-implemented method of claim 34.

37. and further comprising establishing a communications session with a remote client terminal of a healthcare provider and / or a public health entity in response to the diagnosis, prognosis, or trend.

37. The computer-implemented method of claim 36.

38. administering to the user a therapy effective to treat the medical condition.

37. The computer-implemented method of claim 36.

39. determining concentrations of wellness biomarkers containing non-diagnostic information; automatically communicating the non-diagnostic information to a client terminal via a connected smart device; 35. The computer-implemented method of claim 34, further comprising:

40. The health condition is a non-reportable, non-life-threatening health condition that does not require diagnosis by a medical professional, as classified by various biomarker levels; 40. The computer-implemented method of claim 39.

41. The biomarker is selected from the group consisting of salivary cortisol, blood-based cortisol, testosterone, interleukin-6 (IL-6), tetrahydrocannabinol (THC) influenza A, influenza B, group A streptococcus, procalcitonin, C-reactive protein, and Escherichia coli; 40. The computer-implemented method of claim 39.

42. the medical condition is an infection caused by an infectious agent; 35. The computer-implemented method of claim 34.

43. 43. The computer-implemented method of claim 42, wherein the infectious disease pathogen is selected from the group consisting of a sexually transmitted disease and COVID-19.

44. analyzing includes providing the signal to a machine learning model trained on a training dataset including a plurality of records; each record includes a sample signal labeled with at least one ground truth indicator of evidence of the presence of at least one of the analytes, evidence of the absence of the presence of at least one of the analytes, and a concentration of at least one of the analytes; 35. The computer-implemented method of claim 34.

45. the received signal is calculated from signals output by a test electronic sensor sensing at least one of said sensing areas and a reference electronic sensor sensing a reference area different from said at least one sensing area, At least one of the analytes that bind to the analyte binding element in at least one of the sensing regions does not selectively bind to the reference region.

35. The computer-implemented method of claim 34.

46. deploying a plurality of rolls having components for creating a plurality of test devices; unfolding a roll of flexible planar elements having a plurality of spaced apart electronic sensors disposed thereon; Laminating an adhesive substrate onto a surface of the flexible planar element; laminating components for producing a plurality of said test devices onto said adhesive substrate to produce a master assembly; Slicing the master assembly into a plurality of slices; each slice representing a respective test device of the plurality of test devices for evaluating the presence, absence, and / or concentration of at least one analyte in an applied sample; A method for manufacturing an inspection device.

47. The flexible planar element includes a flexible printed circuit board (PCB); 47. A method of manufacturing a test device according to claim 46.

48. Unfold the roll of self-adhesive tape, Laminating the unfolded self-adhesive tape onto the surface of the flexible planar element; Further including: laminating includes sandwiching the self-adhesive tape between the flexible planar element and the components of the plurality of testing devices.

47. A method of manufacturing a test device according to claim 46.

49. and slicing includes slicing along a width of the master assembly between adjacent electronic sensors.

47. A method of manufacturing a test device according to claim 46.

50. Each respective testing device: a planar element of said roll of flexible planar elements; at least one electronic sensor of the plurality of electronic sensors of the roll of flexible planar element; and an adhesive substrate connected to the surface of the planar element and to the surface of the lateral flow test element for fixing at least one of the electronic sensors in a position facing at least one sensing area including an analyte binding element designed to bind to at least one of the analytes administered to the lateral flow test element.

47. A method of manufacturing a test device according to claim 46.

Citation Information

Patent Citations

  • Magnetic sensor device with field compensation

    CN101283264A

  • Measuring instrument, measuring kit using it, measuring method and measuring device

    JP2007040717A

  • Magnetic sensor device, method of operating such device, and sample

    JP2012532312A

  • Sensor integration and its applications in lateral flow immunoassays

    JP2015535341A

  • Generation of pH / Temperature / Ion Gradients in a Lateral Flow Immunoassay for Modulating Biomolecular Interactions and Use Thereof

    JP2016511423A